Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Tan, M.P. Harris, V. Warren-Oseni, K. McDonald, F. McNair, H. Taylor, H. Hansen, V. Sharabiani, M. Thomas, K. Jones, K. Dearnaley, D. Hafeez, S. Huddart, R.A. (2020). The Intensity-Modulated Pelvic Node and Bladder Radiotherapy (IMPART) Trial: A Phase II Single-Centre Prospective Study. Clinical oncology, Vol.32 (2), pp. 93-100.

Murray, J.R. Tree, A.C. Alexander, E.J. Sohaib, A. Hazell, S. Thomas, K. Gunapala, R. Parker, C.C. Huddart, R.A. Gao, A. Truelove, L. McNair, H.A. Blasiak-Wal, I. deSouza, N.M. Dearnaley, D. (2020). Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: Efficacy and Toxicity in the DELINEATE Trial. International journal of radiation oncology*biology*physics, Vol.106 (4), pp. 715-724.

Cafferty, F.H. White, J.D. Shamash, J. Hennig, I. Stenning, S.P. Huddart, R.A. (2020). Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604). European journal of cancer, Vol.127, pp. 139-149.

Patel, K. Choudhury, A. Hoskin, P. Varughese, M. James, N. Huddart, R. Birtle, A. (2020). Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review. Clinical oncology, Vol.32 (6), pp. 347-353.

Huddart, R. Joffe, J. Cullen, M. (2020). Reply to Torgrim Tandstad The New Standard Adjuvant Treatment for High-risk Stage 1 Nonseminoma: Reducing the Treatment Burden and Maximizing Long-term Survival Eur Urol 2020;77:352–3. European urology, .

Loveday, C. Litchfield, K. Proszek, P.Z. Cornish, A.J. Santo, F. Levy, M. Macintyre, G. Holryod, A. Broderick, P. Dudakia, D. Benton, B. Bakir, M.A. Hiley, C. Grist, E. Swanton, C. Huddart, R. Powles, T. Chowdhury, S. Shipley, J. O’Connor, S. Brenton, J.D. Reid, A. de Castro, D.G. Houlston, R.S. Turnbull, C. (2020). Genomic landscape of platinum resistant and sensitive testicular cancers. Nature communications, Vol.11 (1).

El Charif, O. Mapes, B. Trendowski, M.R. Wheeler, H.E. Wing, C. Dinh, P.C. Frisina, R.D. Feldman, D.R. Hamilton, R.J. Vaughn, D.J. Fung, C. Kollmannsberger, C. Mushiroda, T. Kubo, M. Gamazon, E.R. Cox, N.J. Huddart, R. Ardeshir-Rouhani-Fard, S. Monahan, P. Fossa, S.D. Einhorn, L.H. Travis, L.B. Dolan, M.E. (2019). Clinical and Genome-wide Analysis of Cisplatin-induced Tinnitus Implicates Novel Ototoxic Mechanisms. Clinical cancer research, Vol.25 (13), pp. 4104-4116.

Pathmanathan, A.U. McNair, H.A. Schmidt, M.A. Brand, D.H. Delacroix, L. Eccles, C.L. Gordon, A. Herbert, T. van As, N.J. Huddart, R.A. Tree, A.C. (2019). Comparison of prostate delineation on multimodality imaging for MR-guided radiotherapy. Br j radiol, Vol.92 (1095), pp. 20180948-20180948.  show abstract

Abu Zaid, M. Dinh, P.C. Monahan, P.O. Fung, C. El-Charif, O. Feldman, D.R. Hamilton, R.J. Vaughn, D.J. Beard, C.J. Cook, R. Althouse, S. Ardeshir-Rouhani-Fard, S. Sesso, H.D. Huddart, R. Mushiroda, T. Kubo, M. Dolan, M.E. Einhorn, L.H. Fossa, S.D. Travis, L.B. _, _. (2019). Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. Journal of the national comprehensive cancer network, Vol.17 (5), pp. 459-468.  show abstract

Walker, A.K. Karaszi, K. Valentine, H. Strauss, V.Y. Choudhury, A. McGill, S. Wen, K. Brown, M.D. Ramani, V. Bhattarai, S. Teo, M.T. Yang, L. Myers, K.A. Deshmukh, N. Denley, H. Browning, L. Love, S.B. Iyer, G. Clarke, N.W. Hall, E. Huddart, R. James, N.D. Hoskin, P.J. West, C.M. Kiltie, A.E. (2019). MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. International journal of radiation oncology*biology*physics, Vol.104 (4), pp. 809-818.

Loveday, C. Sud, A. Litchfield, K. Levy, M. Holroyd, A. Broderick, P. Kote-Jarai, Z. Dunning, A.M. Muir, K. Peto, J. Eeles, R. Easton, D.F. Dudakia, D. Orr, N. Pashayan, N. Reid, A. Huddart, R.A. Houlston, R.S. Turnbull, C. (2019). Runs of homozygosity and testicular cancer risk. Andrology, Vol.7 (4), pp. 555-564.

Patel, E. Tsang, Y. Baker, A. Callender, J. Hafeez, S. Hall, E. Hansen, V.N. Lewis, R. McNair, H. Miles, E. Huddart, R. (2019). Quality assuring “Plan of the day” selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module. Clinical and translational radiation oncology, Vol.19, pp. 27-32.

Brand, D.H. Parker, J.I. Dearnaley, D.P. Eeles, R. Huddart, R. Khoo, V. Murray, J. Suh, Y.-. Tree, A.C. van As, N. Parker, C. (2019). Patterns of recurrence after prostate bed radiotherapy. Radiotherapy and oncology, Vol.141, pp. 174-180.

Eccles, C.L. Adair Smith, G. Bower, L. Hafeez, S. Herbert, T. Hunt, A. McNair, H.A. Ofuya, M. Oelfke, U. Nill, S. Huddart, R.A. (2019). Magnetic resonance imaging sequence evaluation of an MR Linac system; early clinical experience. Technical innovations & patient support in radiation oncology, Vol.12, pp. 56-63.

Loriot, Y. Necchi, A. Park, S.H. Garcia-Donas, J. Huddart, R. Burgess, E. Fleming, M. Rezazadeh, A. Mellado, B. Varlamov, S. Joshi, M. Duran, I. Tagawa, S.T. Zakharia, Y. Zhong, B. Stuyckens, K. Santiago-Walker, A. De Porre, P. O’Hagan, A. Avadhani, A. Siefker-Radtke, A.O. (2019). Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New england journal of medicine, Vol.381 (4), pp. 338-348.

Hall, E. Huddart, R. Lewis, R. Porta, N. (2019). The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. European urology, .

Selfe, J. Goddard, N.C. McIntyre, A. Taylor, K.R. Renshaw, J. Popov, S.D. Thway, K. Summersgill, B. Huddart, R.A. Gilbert, D.C. Shipley, J.M. (2018). IGF1R signalling in testicular germ cell tumour cells impacts on cell survival and acquired cisplatin resistance. The journal of pathology, Vol.244 (2), pp. 242-253.

Litchfield, K. Loveday, C. Levy, M. Dudakia, D. Rapley, E. Nsengimana, J. Bishop, D.T. Reid, A. Huddart, R. Broderick, P. Houlston, R.S. Turnbull, C. (2018). Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. European urology, Vol.73 (6), pp. 828-831.

Tree, A.C. Jones, K. Hafeez, S. Sharabiani, M.T. Harrington, K.J. Lalondrelle, S. Ahmed, M. Huddart, R.A. (2018). Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer. International journal of radiation oncology*biology*physics, Vol.101 (5), pp. 1168-1171.

Honecker, F. Aparicio, J. Berney, D. Beyer, J. Bokemeyer, C. Cathomas, R. Clarke, N. Cohn-Cedermark, G. Daugaard, G. Dieckmann, K.-. Fizazi, K. Fosså, S. Germa-Lluch, J.R. Giannatempo, P. Gietema, J.A. Gillessen, S. Haugnes, H.S. Heidenreich, A. Hemminki, K. Huddart, R. Jewett, M.A. Joly, F. Lauritsen, J. Lorch, A. Necchi, A. Nicolai, N. Oing, C. Oldenburg, J. Ondruš, D. Papachristofilou, A. Powles, T. Sohaib, A. Ståhl, O. Tandstad, T. Toner, G. Horwich, A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of oncology, Vol.29 (8), pp. 1658-1686.

Panebianco, V. Narumi, Y. Altun, E. Bochner, B.H. Efstathiou, J.A. Hafeez, S. Huddart, R. Kennish, S. Lerner, S. Montironi, R. Muglia, V.F. Salomon, G. Thomas, S. Vargas, H.A. Witjes, J.A. Takeuchi, M. Barentsz, J. Catto, J.W. (2018). Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). European urology, Vol.74 (3), pp. 294-306.

Loveday, C. Law, P. Litchfield, K. Levy, M. Holroyd, A. Broderick, P. Kote-Jarai, Z. Dunning, A.M. Muir, K. Peto, J. Eeles, R. Easton, D.F. Dudakia, D. Orr, N. Pashayan, N. Reid, A. Huddart, R.A. Houlston, R.S. Turnbull, C. (2018). Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. European urology, Vol.74 (3), pp. 248-252.

Tree, A.C. Huddart, R. Choudhury, A. (2018). Magnetic Resonance-guided Radiotherapy — Can We Justify More Expensive Technology?. Clinical oncology, Vol.30 (11), pp. 677-679.

Crabb, S. Danson, S.J. Catto, J.W. McDowell, C. Lowder, J.N. Caddy, J. Dunkley, D. Rajaram, J. Ellis, D. Hill, S. Hathorn, D. Whitehead, A. Kalevras, M. Huddart, R. Griffiths, G. (2018). SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial. Trials, Vol.19 (1).

Hussain, S.A. Birtle, A. Crabb, S. Huddart, R. Small, D. Summerhayes, M. Jones, R. Protheroe, A. (2018). From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. European urology oncology, Vol.1 (6), pp. 486-500.

Kerns, S.L. Fung, C. Monahan, P.O. Ardeshir-Rouhani-Fard, S. Abu Zaid, M.I. Williams, A.M. Stump, T.E. Sesso, H.D. Feldman, D.R. Hamilton, R.J. Vaughn, D.J. Beard, C. Huddart, R.A. Kim, J. Kollmannsberger, C. Sahasrabudhe, D.M. Cook, R. Fossa, S.D. Einhorn, L.H. Travis, L.B. Platinum Study Group, (2018). Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. J clin oncol, Vol.36 (15), pp. 1505-1512.  show abstract

Loveday, C. Litchfield, K. Levy, M. Holroyd, A. Broderick, P. Kote-Jarai, Z. Dunning, A.M. Muir, K. Peto, J. Eeles, R. Easton, D.F. Dudakia, D. Orr, N. Pashayan, N. Reid, A. Huddart, R.A. Houlston, R.S. Turnbull, C. (2018). Validation of loci at 2q14 2 and 15q21 3 as risk factors for testicular cancer. Oncotarget, Vol.9 (16), pp. 12630-12638.

Huddart, R.A. Reid, A.M. (2018). Adjuvant Therapy for Stage IB Germ Cell Tumors: One versus Two Cycles of BEP. Advances in urology, Vol.2018, pp. 1-6.  show abstract

Powles, T. Huddart, R.A. Elliott, T. Sarker, S.-. Ackerman, C. Jones, R. Hussain, S. Crabb, S. Jagdev, S. Chester, J. Hilman, S. Beresford, M. Macdonald, G. Santhanam, S. Frew, J.A. Stockdale, A. Hughes, S. Berney, D. Chowdhury, S. (2017). Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. J clin oncol, Vol.35 (1), pp. 48-55.  show abstract

Shamash, J. Sarker, S.-. Huddart, R. Harland, S. Joffe, J.K. Mazhar, D. Birtle, A. White, J. Chowdhury, K. Wilson, P. Marshall, M.R. Vinnicombe, S. (2017). A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann oncol, Vol.28 (6), pp. 1333-1338.  show abstract

Jones, R.J. Hussain, S.A. Protheroe, A.S. Birtle, A. Chakraborti, P. Huddart, R.A. Jagdev, S. Bahl, A. Stockdale, A. Sundar, S. Crabb, S.J. Dixon-Hughes, J. Alexander, L. Morris, A. Kelly, C. Stobo, J. Paul, J. Powles, T. (2017). Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. J clin oncol, Vol.35 (16), pp. 1770-1777.  show abstract

Choudhury, A. West, C.M. Porta, N. Hall, E. Denley, H. Hendron, C. Lewis, R. Hussain, S.A. Huddart, R. James, N. (2017). The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). British journal of cancer, Vol.116 (5), pp. 649-657.

Hussain, S.A. Ansari, J. Huddart, R. Powers, D.G. Lyons, J. Wylie, J. Vilarino-Varlela, M. Elander, N.O. McMenemin, R. Pickering, L.M. Faust, G. Chauhan, S. Jackson, R.J. (2017). VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. International journal of oncology, Vol.50 (3), pp. 768-772.

Hafeez, S. McDonald, F. Lalondrelle, S. McNair, H. Warren-Oseni, K. Jones, K. Harris, V. Taylor, H. Khoo, V. Thomas, K. Hansen, V. Dearnaley, D. Horwich, A. Huddart, R. (2017). Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment. International journal of radiation oncology*biology*physics, Vol.98 (1), pp. 115-122.

Trainor, S. Choudhury, A. Huddart, R. Kiltie, A.E. Kockelbergh, R. Turner, W. Birtle, A. Crabb, S.J. (2017). The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?. Clinical oncology, Vol.29 (6), pp. 344-347.

Litchfield, K. Levy, M. Orlando, G. Loveday, C. Law, P.J. Migliorini, G. Holroyd, A. Broderick, P. Karlsson, R. Haugen, T.B. Kristiansen, W. Nsengimana, J. Fenwick, K. Assiotis, I. Kote-Jarai, Z. Dunning, A.M. Muir, K. Peto, J. Eeles, R. Easton, D.F. Dudakia, D. Orr, N. Pashayan, N. Bishop, D.T. Reid, A. Huddart, R.A. Shipley, J. Grotmol, T. Wiklund, F. Houlston, R.S. Turnbull, C. (2017). Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nature genetics, Vol.49 (7), pp. 1133-1140.

Levy, M. Hall, D. Sud, A. Law, P. Litchfield, K. Dudakia, D. Haugen, T.B. Karlsson, R. Reid, A. Huddart, R.A. Grotmol, T. Wiklund, F. Houlston, R.S. Turnbull, C. (2017). Mendelian randomisation analysis provides no evidence for a relationship between adult height and testicular cancer risk. Andrology, Vol.5 (5), pp. 914-922.

Patrikidou, A. Uccello, M. Tree, A. Parker, C. Attard, G. Eeles, R. Khoo, V. van As, N. Huddart, R. Dearnaley, D. Reid, A. (2017). Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. Clinical oncology, Vol.29 (10), pp. e174-e175.

Crabb, S.J. Martin, K. Abab, J. Ratcliffe, I. Thornton, R. Lineton, B. Ellis, M. Moody, R. Stanton, L. Galanopoulou, A. Maishman, T. Geldart, T. Bayne, M. Davies, J. Lamb, C. Popat, S. Joffe, J.K. Nutting, C. Chester, J. Hartley, A. Thomas, G. Ottensmeier, C. Huddart, R. King, E. (2017). COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European journal of cancer, Vol.87, pp. 75-83.

Gilbert, D.C. Al-Saadi, R. Thway, K. Chandler, I. Berney, D. Gabe, R. Stenning, S.P. Sweet, J. Huddart, R. Shipley, J.M. (2016). Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. Clinical cancer research, Vol.22 (5), pp. 1265-1273.

Feldman, D.R. Lorch, A. Kramar, A. Albany, C. Einhorn, L.H. Giannatempo, P. Necchi, A. Flechon, A. Boyle, H. Chung, P. Huddart, R.A. Bokemeyer, C. Tryakin, A. Sava, T. Winquist, E.W. De Giorgi, U. Aparicio, J. Sweeney, C.J. Cohn Cedermark, G. Beyer, J. Powles, T. (2016). Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options—An Analysis From the Global Germ Cell Cancer Group. Journal of clinical oncology, Vol.34 (4), pp. 345-351.  show abstract

Vestergaard, A. Hafeez, S. Muren, L.P. Nill, S. Høyer, M. Hansen, V.N. Grønborg, C. Pedersen, E.M. Petersen, J.B. Huddart, R. Oelfke, U. (2016). The potential of MRI-guided online adaptive re-optimisation in radiotherapy of urinary bladder cancer. Radiotherapy and oncology, Vol.118 (1), pp. 154-159.

Sternberg, C. Armstrong, A. Pili, R. Ng, S. Huddart, R. Agarwal, N. Khvorostenko, D. Lyulko, O. Brize, A. Vogelzang, N. Delva, R. Harza, M. Thanos, A. James, N. Werbrouck, P. Bögemann, M. Hutson, T. Milecki, P. Chowdhury, S. Gallardo, E. Schwartsmann, G. Pouget, J.-. Baton, F. Nederman, T. Tuvesson, H. Carducci, M. (2016). Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. J clin oncol, Vol.34 (22), pp. 2636-2643.  show abstract

Hafeez, S. Warren-Oseni, K. McNair, H.A. Hansen, V.N. Jones, K. Tan, M. Khan, A. Harris, V. McDonald, F. Lalondrelle, S. Mohammed, K. Thomas, K. Thompson, A. Kumar, P. Dearnaley, D. Horwich, A. Huddart, R. (2016). Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer. International journal of radiation oncology*biology*physics, Vol.94 (5), pp. 1022-1030.

Litchfield, K. Levy, M. Huddart, R.A. Shipley, J. Turnbull, C. (2016). The genomic landscape of testicular germ cell tumours: from susceptibility to treatment. Nat rev urol, Vol.13 (7), pp. 409-419.  show abstract

Pathmanathan, A.U. Alexander, E.J. Huddart, R.A. Tree, A.C. (2016). The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging. Future oncol, Vol.12 (21), pp. 2495-2511.  show abstract

Murray, M.J. Huddart, R.A. Coleman, N. (2016). The present and future of serum diagnostic tests for testicular germ cell tumours. Nat rev urol, Vol.13 (12), pp. 715-725.  show abstract

Litchfield, K. Levy, M. Dudakia, D. Proszek, P. Shipley, C. Basten, S. Rapley, E. Bishop, D.T. Reid, A. Huddart, R. Broderick, P. Castro, D.G. O'Connor, S. Giles, R.H. Houlston, R.S. Turnbull, C. (2016). Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. Nature communications, Vol.7 (1).

McDonald, F. Waters, R. Gulliford, S. Hall, E. James, N. Huddart, R.A. (2015). Defining bowel dose volume constraints for bladder radiotherapy treatment planning. Clin oncol (r coll radiol), Vol.27 (1), pp. 22-29.  show abstract

Huddart, R.A. Gabe, R. Cafferty, F.H. Pollock, P. White, J.D. Shamash, J. Cullen, M.H. Stenning, S.P. Collabor, T.T. Clin, N.C. (2015). A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). European urology, Vol.67 (3), pp. 534-543.

Tan, M. Jones, K. Thomas, K. Huddart, R. (2015). Small Cell Carcinoma of the Bladder: A Single Centre Experience 2001–2013. Clinical oncology, Vol.27 (3), pp. e6-e6.

Venkitaraman, R. Lorente, D. Murthy, V. Thomas, K. Parker, L. Ahiabor, R. Dearnaley, D. Huddart, R. De Bono, J. Parker, C. (2015). A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur urol, Vol.67 (4), pp. 673-679.  show abstract

Geldart, T. Chester, J. Casbard, A. Crabb, S. Elliott, T. Protheroe, A. Huddart, R.A. Mead, G. Barber, J. Jones, R.J. Smith, J. Cowles, R. Evans, J. Griffiths, G. (2015). SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma. Eur urol, Vol.67 (4), pp. 599-602.  show abstract

Huddart, R. (2015). New insight into the aetiology of testicular germ cell tumours. Eur urol, Vol.67 (4), pp. 702-703.

McNair, H.A. Hafeez, S. Taylor, H. Lalondrelle, S. McDonald, F. Hansen, V.N. Huddart, R. (2015). Radiographer-led plan selection for bladder cancer radiotherapy: initiating a training programme and maintaining competency. Br j radiol, Vol.88 (1048), p. 20140690.  show abstract

Cook, G.J. Sohaib, A. Huddart, R.A. Dearnaley, D.P. Horwich, A. Chua, S. (2015). The role of 18F-FDG PET/CT in the management of testicular cancers. Nuclear medicine communications, Vol.36 (7), pp. 702-708.

Huddart, R.A. Jones, R. Choudhury, A. (2015). A New Dawn for Bladder Cancer? Recommendations from the National Institute for Health and Care Excellence (NICE) on Managing Bladder Cancer. Clinical oncology, Vol.27 (7), pp. 380-381.

Evans, C.M. Burnet, N.G. Hall, E. Huddart, R.A. Nutting, C.M. Coles, C.E. (2015). The Radiotherapy Clinical Trial Research Landscape in the UK Between 2004 and 2013: A Cross-sectional Analysis. Clinical oncology, Vol.27 (9), pp. 491-494.

Ananya, C. West, C. Porta, N. Denley, H. Hendron, C. Hussain, S. Hall, E. Huddart, R. James, N. (2015). The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 (CRUK/01/004) trial. European journal of cancer, Vol.51, pp. S527-S528.

West, C.M. Huddart, R.A. (2015). Biomarkers and Imaging for Precision Radiotherapy. Clinical oncology, Vol.27 (10), pp. 545-546.

McNair, H.A. Harris, E.J. Hansen, V.N. Thomas, K. South, C. Hafeez, S. Huddart, R. Dearnaley, D.P. (2015). Magnitude of observer error using cone beam CT for prostate interfraction motion estimation: effect of reducing scan length or increasing exposure. The british journal of radiology, Vol.88 (1054), pp. 20150208-20150208.

Litchfield, K. Mitchell, J.S. Shipley, J. Huddart, R. Rajpert-De Meyts, E. Skakkebæk, N.E. Houlston, R.S. Turnbull, C. (2015). Polygenic susceptibility to testicular cancer: implications for personalised health care. British journal of cancer, Vol.113 (10), pp. 1512-1518.

Hafeez, S. Horwich, A. Omar, O. Mohammed, K. Thompson, A. Kumar, P. Khoo, V. Van As, N. Eeles, R. Dearnaley, D. Huddart, R. (2015). Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. British journal of cancer, Vol.112 (10), pp. 1626-1635.

Hafeez, S. Singhera, M. Huddart, R. (2015). Exploration of the treatment challenges in men with intellectual difficulties and testicular cancer as seen in Down syndrome: single centre experience. Bmc medicine, Vol.13 (1).

Litchfield, K. Holroyd, A. Lloyd, A. Broderick, P. Nsengimana, J. Eeles, R. Easton, D.F. Dudakia, D. Bishop, D.T. Reid, A. Huddart, R.A. Grotmol, T. Wiklund, F. Shipley, J. Houlston, R.S. Turnbull, C. (2015). Identification of four new susceptibility loci for testicular germ cell tumour. Nature communications, Vol.6 (1).

Litchfield, K. Sultana, R. Renwick, A. Dudakia, D. Seal, S. Ramsay, E. Powell, S. Elliott, A. Warren-Perry, M. Eeles, R. Peto, J. Kote-Jarai, Z. Muir, K. Nsengimana, J. UKTCC, Stratton, M.R. Easton, D.F. Bishop, D.T. Huddart, R.A. Rahman, N. Turnbull, C. UKTCC, (2015). Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25. Hum mol genet, Vol.24 (4), pp. 1169-1176.  show abstract

Olson, T.A. Murray, M.J. Rodriguez-Galindo, C. Nicholson, J.C. Billmire, D.F. Krailo, M.D. Dang, H.M. Amatruda, J.F. Thornton, C.M. Arul, G.S. Stoneham, S.J. Pashankar, F. Stark, D. Shaikh, F. Gershenson, D.M. Covens, A. Hurteau, J. Stenning, S.P. Feldman, D.R. Grimison, P.S. Huddart, R.A. Sweeney, C. Powles, T. Lopes, L.F. dos Santos Agular, S. Chinnaswamy, G. Khaleel, S. Abouelnaga, S. Hale, J.P. Frazier, A.L. (2015). Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal of clinical oncology, Vol.33 (27), pp. 3018-3028.  show abstract

Litchfield, K. Summersgill, B. Yost, S. Sultana, R. Labreche, K. Dudakia, D. Renwick, A. Seal, S. Al-Saadi, R. Broderick, P. Turner, N.C. Houlston, R.S. Huddart, R. Shipley, J. Turnbull, C. (2015). Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours. Nat commun, Vol.6, p. 5973.  show abstract

Dearnaley, D.P. Jovic, G. Syndikus, I. Khoo, V. Cowan, R.A. Graham, J.D. Aird, E.G. Bottomley, D. Huddart, R.A. Jose, C.C. Matthews, J.H. Millar, J.L. Murphy, C. Russell, J.M. Scrase, C.D. Parmar, M.K. Sydes, M.R. (2014). Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet oncol, Vol.15 (4), pp. 464-473.  show abstract

Huddart, R.A. Hall, E. Hussain, S.A. Jenkins, P. Rawlings, C. Tremlett, J. Crundwell, M. Adab, F.A. Sheehan, D. Syndikus, I. Hendron, C. Lewis, R. Waters, R. James, N.D. (2014). Re: Randomized Noninferiority Trial of Reduced High-Dose Volume versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004) Editorial Comment. Journal of urology, Vol.191 (6), pp. 1731-1731.

Hafeez, S. McNair, H. Warren-Oseni, K. Hansen, V. Huddart, R. (2014). Audit of Radiographer Led Plan Selection in Imaged Guided Adaptive Radiotherapy (IGART) for Bladder Cancer. Clinical oncology, Vol.26, pp. S7-S8.

Hafeez, S. Huddart, R. (2014). Audit of Patient Pathway for those Receiving Radical Radiotherapy for Bladder Cancer. Clinical oncology, Vol.26, pp. S9-S10.

Horwich, A. Fossa, S.D. Huddart, R. Dearnaley, D.P. Stenning, S. Aresu, M. Bliss, J.M. Hall, E. (2014). Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. Br j cancer, Vol.110 (1), pp. 256-263.  show abstract

Parker, C. Venkitaraman, R. Lorente, D. Murthy, V. Thomas, K. Ahiabor, R. Dearnaley, D. Huddart, R. de Bono, J.S. (2014). A Randomised Phase Ii Trial of Dexamethasone Versus Prednisolone in Castration Resistant Prostate Cancer. Annals of oncology, Vol.25, pp. iv260-iv260.

Beyer, J. Lorch, A. Powles, T. Kramar, A. van Alstine, L. Giannatempo, P. Sava, T. Albany, C. Einhorn, L. Flechon, A. Aparicio, J. Chung, P. Huddart, R.A. Bokemeyer, C. Tryakin, A. Winquist, E. Sweeney, C. Hentrich, M. Margolin, K. Feldman, D.R. (2014). Brain Metastases in Male Germ Cell Tumors (Gct): a Large Retrospective Analysis on Behalf of the Swenoteca and the G3 Consortium. Annals of oncology, Vol.25, pp. iv282-iv282.

Hafeez, S. Huddart, R. (2014). Selective organ preservation for the treatment of muscle-invasive transitional cell carcinoma of the bladder: a review of current and future perspectives. Expert rev anticancer ther, Vol.14 (12), pp. 1429-1443.  show abstract

Maund, I.F. Benson, R.J. Fairfoul, J. Cook, J. Huddart, R. Poynter, A. (2014). Image-guided radiotherapy of the prostate using daily CBCT: the feasibility and likely benefit of implementing a margin reduction. Br j radiol, Vol.87 (1044), p. 20140459.  show abstract

Tree, A.C. Khoo, V.S. Eeles, R.A. Ahmed, M. Dearnaley, D.P. Hawkins, M.A. Huddart, R.A. Nutting, C.M. Ostler, P.J. van As, N.J. (2013). Stereotactic body radiotherapy for oligometastases. Lancet oncol, Vol.14 (1), pp. e28-e37.  show abstract

Huddart, R.A. Hall, E. Hussain, S.A. Jenkins, P. Rawlings, C. Tremlett, J. Crundwell, M. Adab, F.A. Sheehan, D. Syndikus, I. Hendron, C. Lewis, R. Waters, R. James, N.D. (2013). Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). Int j radiat oncol biol phys, Vol.87 (2), pp. 261-269.  show abstract

Payne, H. Clarke, N. Huddart, R. Parker, C. Troup, J. Graham, J. (2013). Nasty or Nice? Findings from a UK Survey to evaluate the impact of the National Institute for Health and Clinical Excellence (NICE) clinical guidelines on the management of prostate cancer. Clin oncol (r coll radiol), Vol.25 (3), pp. 178-189.  show abstract

Miller, R.E. Dudderidge, T. Huddart, R. Seckl, M.J. Rustin, G.J. Christmas, T.J. (2013). Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. Bju int, Vol.111 (4 Pt B), pp. E152-E157.  show abstract

Beyer, J. Albers, P. Altena, R. Aparicio, J. Bokemeyer, C. Busch, J. Cathomas, R. Cavallin-Stahl, E. Clarke, N.W. Claßen, J. Cohn-Cedermark, G. Dahl, A.A. Daugaard, G. De Giorgi, U. De Santis, M. De Wit, M. De Wit, R. Dieckmann, K.P. Fenner, M. Fizazi, K. Flechon, A. Fossa, S.D. Germá Lluch, J.R. Gietema, J.A. Gillessen, S. Giwercman, A. Hartmann, J.T. Heidenreich, A. Hentrich, M. Honecker, F. Horwich, A. Huddart, R.A. Kliesch, S. Kollmannsberger, C. Krege, S. Laguna, M.P. Looijenga, L.H. Lorch, A. Lotz, J.P. Mayer, F. Necchi, A. Nicolai, N. Nuver, J. Oechsle, K. Oldenburg, J. Oosterhuis, J.W. Powles, T. Rajpert-De Meyts, E. Rick, O. Rosti, G. Salvioni, R. Schrader, M. Schweyer, S. Sedlmayer, F. Sohaib, A. Souchon, R. Tandstad, T. Winter, C. Wittekind, C. (2013). Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann oncol, Vol.24 (4), pp. 878-888.  show abstract

Eeles, R.A. Olama, A.A. Benlloch, S. Saunders, E.J. Leongamornlert, D.A. Tymrakiewicz, M. Ghoussaini, M. Luccarini, C. Dennis, J. Jugurnauth-Little, S. Dadaev, T. Neal, D.E. Hamdy, F.C. Donovan, J.L. Muir, K. Giles, G.G. Severi, G. Wiklund, F. Gronberg, H. Haiman, C.A. Schumacher, F. Henderson, B.E. Le Marchand, L. Lindstrom, S. Kraft, P. Hunter, D.J. Gapstur, S. Chanock, S.J. Berndt, S.I. Albanes, D. Andriole, G. Schleutker, J. Weischer, M. Canzian, F. Riboli, E. Key, T.J. Travis, R.C. Campa, D. Ingles, S.A. John, E.M. Hayes, R.B. Pharoah, P.D. Pashayan, N. Khaw, K.-. Stanford, J.L. Ostrander, E.A. Signorello, L.B. Thibodeau, S.N. Schaid, D. Maier, C. Vogel, W. Kibel, A.S. Cybulski, C. Lubinski, J. Cannon-Albright, L. Brenner, H. Park, J.Y. Kaneva, R. Batra, J. Spurdle, A.B. Clements, J.A. Teixeira, M.R. Dicks, E. Lee, A. Dunning, A.M. Baynes, C. Conroy, D. Maranian, M.J. Ahmed, S. Govindasami, K. Guy, M. Wilkinson, R.A. Sawyer, E.J. Morgan, A. Dearnaley, D.P. Horwich, A. Huddart, R.A. Khoo, V.S. Parker, C.C. Van As, N.J. Woodhouse, C.J. Thompson, A. Dudderidge, T. Ogden, C. Cooper, C.S. Lophatananon, A. Cox, A. Southey, M.C. Hopper, J.L. English, D.R. Aly, M. Adolfsson, J. Xu, J. Zheng, S.L. Yeager, M. Kaaks, R. Diver, W.R. Gaudet, M.M. Stern, M.C. Corral, R. Joshi, A.D. Shahabi, A. Wahlfors, T. Tammela, T.L. Auvinen, A. Virtamo, J. Klarskov, P. Nordestgaard, B.G. Røder, M.A. Nielsen, S.F. Bojesen, S.E. Siddiq, A. Fitzgerald, L.M. Kolb, S. Kwon, E.M. Karyadi, D.M. Blot, W.J. Zheng, W. Cai, Q. McDonnell, S.K. Rinckleb, A.E. Drake, B. Colditz, G. Wokolorczyk, D. Stephenson, R.A. Teerlink, C. Muller, H. Rothenbacher, D. Sellers, T.A. Lin, H.-. Slavov, C. Mitev, V. Lose, F. Srinivasan, S. Maia, S. Paulo, P. Lange, E. Cooney, K.A. Antoniou, A.C. Vincent, D. Bacot, F. Tessier, D.C. COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative, Australian Prostate Cancer Bioresource, UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai, Z. Easton, D.F. (2013). Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat genet, Vol.45 (4), pp. 385-391e2.  show abstract

Miller, R.E. Dudderidge, T. Huddart, R. Seckl, M.J. Rustin, G.J. Christmas, T.J. (2013). Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. Bju international, Vol.111 (4B), pp. E152-E157.

Hafeez, S. Huddart, R. (2013). Outcomes of Selective Organ Preservation with Neoadjuvant Chemotherapy in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Bladder: The Royal Marsden Experience. Clinical oncology, Vol.25 (4), pp. E70-E70.

Singhera, M. Huddart, R. (2013). Testicular cancer: changing patterns of incidence in testicular germ cell tumours. Nat rev urol, Vol.10 (6), pp. 312-314.

Creak, A. Hall, E. Horwich, A. Eeles, R. Khoo, V. Huddart, R. Parker, C. Griffin, C. Bidmead, M. Warrington, J. Dearnaley, D. (2013). Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. Br j cancer, Vol.109 (3), pp. 651-657.  show abstract

Horwich, A. Dearnaley, D.P. Sohaib, A. Pennert, K. Huddart, R.A. (2013). Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann oncol, Vol.24 (8), pp. 2104-2107.  show abstract

McDonald, F. Lalondrelle, S. Taylor, H. Warren-Oseni, K. Khoo, V. McNair, H.A. Harris, V. Hafeez, S. Hansen, V.N. Thomas, K. Jones, K. Dearnaley, D. Horwich, A. Huddart, R. (2013). Clinical implementation of adaptive hypofractionated bladder radiotherapy for improvement in normal tissue irradiation. Clin oncol (r coll radiol), Vol.25 (9), pp. 549-556.  show abstract

Hafeez, S. Huddart, R. (2013). Advances in bladder cancer imaging. Bmc med, Vol.11, p. 104.  show abstract

Payne, H. Adamson, A. Bahl, A. Borwell, J. Dodds, D. Heath, C. Huddart, R. McMenemin, R. Patel, P. Peters, J.L. Thompson, A. (2013). Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. Bju int, Vol.112 (7), pp. 885-897.  show abstract

Selvadurai, E.D. Singhera, M. Thomas, K. Mohammed, K. Woode-Amissah, R. Horwich, A. Huddart, R.A. Dearnaley, D.P. Parker, C.C. (2013). Medium-term outcomes of active surveillance for localised prostate cancer. Eur urol, Vol.64 (6), pp. 981-987.  show abstract

(2013). Erratum. International journal of radiation oncology*biology*physics, Vol.87 (5), pp. 860-860.

Amin Al Olama, A. Kote-Jarai, Z. Schumacher, F.R. Wiklund, F. Berndt, S.I. Benlloch, S. Giles, G.G. Severi, G. Neal, D.E. Hamdy, F.C. Donovan, J.L. Hunter, D.J. Henderson, B.E. Thun, M.J. Gaziano, M. Giovannucci, E.L. Siddiq, A. Travis, R.C. Cox, D.G. Canzian, F. Riboli, E. Key, T.J. Andriole, G. Albanes, D. Hayes, R.B. Schleutker, J. Auvinen, A. Tammela, T.L. Weischer, M. Stanford, J.L. Ostrander, E.A. Cybulski, C. Lubinski, J. Thibodeau, S.N. Schaid, D.J. Sorensen, K.D. Batra, J. Clements, J.A. Chambers, S. Aitken, J. Gardiner, R.A. Maier, C. Vogel, W. Dörk, T. Brenner, H. Habuchi, T. Ingles, S. John, E.M. Dickinson, J.L. Cannon-Albright, L. Teixeira, M.R. Kaneva, R. Zhang, H.-. Lu, Y.-. Park, J.Y. Cooney, K.A. Muir, K.R. Leongamornlert, D.A. Saunders, E. Tymrakiewicz, M. Mahmud, N. Guy, M. Govindasami, K. O'Brien, L.T. Wilkinson, R.A. Hall, A.L. Sawyer, E.J. Dadaev, T. Morrison, J. Dearnaley, D.P. Horwich, A. Huddart, R.A. Khoo, V.S. Parker, C.C. Van As, N. Woodhouse, C.J. Thompson, A. Dudderidge, T. Ogden, C. Cooper, C.S. Lophatonanon, A. Southey, M.C. Hopper, J.L. English, D. Virtamo, J. Le Marchand, L. Campa, D. Kaaks, R. Lindstrom, S. Diver, W.R. Gapstur, S. Yeager, M. Cox, A. Stern, M.C. Corral, R. Aly, M. Isaacs, W. Adolfsson, J. Xu, J. Zheng, S.L. Wahlfors, T. Taari, K. Kujala, P. Klarskov, P. Nordestgaard, B.G. Røder, M.A. Frikke-Schmidt, R. Bojesen, S.E. FitzGerald, L.M. Kolb, S. Kwon, E.M. Karyadi, D.M. Orntoft, T.F. Borre, M. Rinckleb, A. Luedeke, M. Herkommer, K. Meyer, A. Serth, J. Marthick, J.R. Patterson, B. Wokolorczyk, D. Spurdle, A. Lose, F. McDonnell, S.K. Joshi, A.D. Shahabi, A. Pinto, P. Santos, J. Ray, A. Sellers, T.A. Lin, H.-. Stephenson, R.A. Teerlink, C. Muller, H. Rothenbacher, D. Tsuchiya, N. Narita, S. Cao, G.-. Slavov, C. Mitev, V. UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, Australian Prostate Cancer Bioresource, PRACTICAL Consortium, Chanock, S. Gronberg, H. Haiman, C.A. Kraft, P. Easton, D.F. Eeles, R.A. (2013). A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum mol genet, Vol.22 (2), pp. 408-415.  show abstract

Venkitaraman, R. Thomas, K. Murthy, V. Woode-Amissah, R. Dearnaley, D.P. Horwich, A. Huddart, R.A. De Bono, J.S. Parker, C. (2013). A randomized phase II trial of dexamethasone versus prednisolone as secondary hormonal therapy in CRPC. Journal of clinical oncology, Vol.31 (6_suppl), pp. 123-123.  show abstract

Horwich, A. Dearnaley, D.P. Sohaib, A. Pennert, K. Huddart, R.A. (2013). Neoadjuvant carboplatin in stage IIa and IIb seminoma. Journal of clinical oncology, Vol.31 (6_suppl), pp. 321-321.  show abstract

Horwich, A. Nicol, D. Huddart, R. (2013). Testicular germ cell tumours. Bmj, Vol.347, p. f5526.

Singhera, M. Huddart, R. (2013). Comment on 'Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors'. Br j cancer, Vol.109 (9), pp. 2502-2503.

Dearnaley, D. Syndikus, I. Sumo, G. Bidmead, M. Bloomfield, D. Clark, C. Gao, A. Hassan, S. Horwich, A. Huddart, R. Khoo, V. Kirkbride, P. Mayles, H. Mayles, P. Naismith, O. Parker, C. Patterson, H. Russell, M. Scrase, C. South, C. Staffurth, J. Hall, E. (2012). Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet oncol, Vol.13 (1), pp. 43-54.  show abstract

Cafferty, F.H. Gabe, R. Huddart, R.A. Rustin, G. Williams, M.P. Stenning, S.P. Bara, A. Bathia, R. Freeman, S.C. Alder, L. Joffe, J.K. (2012). UK management practices in stage I seminoma and the Medical Research Council Trial of Imaging and Schedule in Seminoma Testis managed with surveillance. Clin oncol (r coll radiol), Vol.24 (1), pp. 25-29.

Singhera, M. Lees, K. Huddart, R. Horwich, A. (2012). Minimizing toxicity in early-stage testicular cancer treatment. Expert rev anticancer ther, Vol.12 (2), pp. 185-193.  show abstract

Lalondrelle, S. Sohaib, S.A. Castellano, I.A. Mears, D. Huddart, R. Khoo, V. (2012). Investigating the relationship between virtual cystoscopy image quality and CT slice thickness. Br j radiol, Vol.85 (1016), pp. 1112-1117.  show abstract

Harris, V. Warren-Oseni, K. Huddart, R.A. (2012). Radiotherapy planning study comparing volumetric modulated arc therapy (VMAT) with intensity modulated radiotherapy (IMRT) in the treatment of bladder and pelvic lymph nodes. Journal of clinical oncology, Vol.30 (5).

Harris, V. Warren-Oseni, K. Huddart, R.A. (2012). Radiotherapy planning study comparing volumetric modulated arc therapy (VMAT) with intensity modulated radiotherapy (IMRT) in the treatment of bladder and pelvic lymph nodes. J clin oncol, Vol.30 (5_suppl), p. 320.  show abstract

Wilkins, A. Shahidi, M. Parker, C. Gunapala, R. Thomas, K. Huddart, R. Horwich, A. Dearnaley, D. (2012). Diethylstilbestrol in castration-resistant prostate cancer. Bju int, Vol.110 (11 Pt B), pp. E727-E735.  show abstract

Zaidi, S. McLaughlin, M. Bhide, S.A. Eccles, S.A. Workman, P. Nutting, C.M. Huddart, R.A. Harrington, K.J. (2012). The HSP90 Inhibitor NVP-AUY922 Radiosensitizes by Abrogation of Homologous Recombination Resulting in Mitotic Entry with Unresolved DNA Damage. Plos one, Vol.7 (4).

James, N.D. Hussain, S.A. Hall, E. Jenkins, P. Tremlett, J. Rawlings, C. Crundwell, M. Sizer, B. Sreenivasan, T. Hendron, C. Lewis, R. Waters, R. Huddart, R.A. BC2001 Investigators, (2012). Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N engl j med, Vol.366 (16), pp. 1477-1488.  show abstract

Cook, G.J. Venkitaraman, R. Sohaib, A.S. Lewington, V.J. Chua, S.C. Huddart, R.A. Parker, C.C. Dearnaley, D.D. Horwich, A. (2011). The diagnostic utility of the flare phenomenon on bone scintigraphy in staging prostate cancer. Eur j nucl med mol imaging, Vol.38 (1), pp. 7-13.  show abstract

Lalondrelle, S. Huddart, R. Warren-Oseni, K. Hansen, V.N. McNair, H. Thomas, K. Dearnaley, D. Horwich, A. Khoo, V. (2011). Adaptive-predictive organ localization using cone-beam computed tomography for improved accuracy in external beam radiotherapy for bladder cancer. Int j radiat oncol biol phys, Vol.79 (3), pp. 705-712.  show abstract

Singhera, M. Johnson, B. Harris, V. Horwich, A. Dearnaley, D.P. Huddart, R.A. (2011). Late CT surveillance in nonseminoma germ cell tumors (NSGCT). Journal of clinical oncology, Vol.29 (7).

Singhera, M. Coffey, J. McDonald, F. Horwich, A. Dearnaley, D.P. Rapley, E. Huddart, R.A. (2011). Anthropomorphic and hormone abnormalities in testicular cancer patients. Journal of clinical oncology, Vol.29 (7).

McDonald, F. Lalondrelle, S. Taylor, H. Harris, V. Hansen, V. Khoo, V. Huddart, R.A. (2011). Adaptive-predictive organ localization (a-POLO) in the clinic: Updated results in hypofractionated bladder radiotherapy. Journal of clinical oncology, Vol.29 (7).

Harris, V. McDonald, F. Hansen, V. Taylor, H. Huddart, R.A. (2011). Planning outcomes and acute toxicity of intensity-modulated radiotherapy (IMRT) for treatment of bladder and pelvic lymph nodes. Journal of clinical oncology, Vol.29 (7).

Mead, G.M. Fossa, S.D. Oliver, R.T. Joffe, J.K. Huddart, R.A. Roberts, J.T. Pollock, P. Gabe, R. Stenning, S.P. MRC/EORTC seminoma trial collaborators, (2011). Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J natl cancer inst, Vol.103 (3), pp. 241-249.  show abstract

Gilbert, D.C. McIntyre, A. Summersgill, B. Missiaglia, E. Goddard, N.C. Chandler, I. Huddart, R.A. Shipley, J. (2011). Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes chromosomes cancer, Vol.50 (3), pp. 186-195.  show abstract

Singhera, M. Coffey, J. McDonald, F. Horwich, A. Dearnaley, D.P. Rapley, E. Huddart, R.A. (2011). Anthropomorphic and hormone abnormalities in testicular cancer patients. J clin oncol, Vol.29 (7_suppl), p. 233.  show abstract

McDonald, F. Lalondrelle, S. Taylor, H. Harris, V. Hansen, V. Khoo, V. Huddart, R.A. (2011). Adaptive-predictive organ localization (a-POLO) in the clinic: Updated results in hypofractionated bladder radiotherapy. J clin oncol, Vol.29 (7_suppl), p. 282.  show abstract

Harris, V. McDonald, F. Hansen, V. Taylor, H. Huddart, R.A. (2011). Planning outcomes and acute toxicity of intensity-modulated radiotherapy (IMRT) for treatment of bladder and pelvic lymph nodes. J clin oncol, Vol.29 (7_suppl), p. 297.  show abstract

Singhera, M. Johnson, B. Harris, V. Horwich, A. Dearnaley, D.P. Huddart, R.A. (2011). Late CT surveillance in nonseminoma germ cell tumors (NSGCT). J clin oncol, Vol.29 (7_suppl), p. 223.  show abstract

Mukhtar, S. Beatty, J. Agrawal, S. Christmas, T.J. Jameson, C. Huddart, R.A. (2011). Germ cell tumour: late recurrence after 43 years. Ann r coll surg engl, Vol.93 (5), pp. e24-e26.  show abstract

Gilbert, D.C. Chandler, I. Summersgill, B. McIntyre, A. Missiaglia, E. Goddard, N.C. Huddart, R.A. Shipley, J. (2011). Genomic gain and over expression of CCL2 correlate with vascular invasion in stage I non-seminomatous testicular germ-cell tumours. Int j androl, Vol.34 (4 Pt 2), pp. e114-e121.  show abstract

Macinnis, R.J. Antoniou, A.C. Eeles, R.A. Severi, G. Al Olama, A.A. McGuffog, L. Kote-Jarai, Z. Guy, M. O'Brien, L.T. Hall, A.L. Wilkinson, R.A. Sawyer, E. Ardern-Jones, A.T. Dearnaley, D.P. Horwich, A. Khoo, V.S. Parker, C.C. Huddart, R.A. Van As, N. McCredie, M.R. English, D.R. Giles, G.G. Hopper, J.L. Easton, D.F. (2011). A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet epidemiol, Vol.35 (6), pp. 549-556.  show abstract

Huddart, R. Horwich, A. Khoo, V. Parker, C. Dearnaley, D. Eeles, R. Kote-Jarai, Z. (2011). A Risk Prediction Algorithm Based on Family History and Common Genetic Variants: Application to Prostate Cancer with Potential Clinical Impact. Genetic epidemiology, Vol.35 (6), pp. 549-556.  show abstract

Kote-Jarai, Z. Olama, A.A. Giles, G.G. Severi, G. Schleutker, J. Weischer, M. Campa, D. Riboli, E. Key, T. Gronberg, H. Hunter, D.J. Kraft, P. Thun, M.J. Ingles, S. Chanock, S. Albanes, D. Hayes, R.B. Neal, D.E. Hamdy, F.C. Donovan, J.L. Pharoah, P. Schumacher, F. Henderson, B.E. Stanford, J.L. Ostrander, E.A. Sorensen, K.D. Dörk, T. Andriole, G. Dickinson, J.L. Cybulski, C. Lubinski, J. Spurdle, A. Clements, J.A. Chambers, S. Aitken, J. Gardiner, R.A. Thibodeau, S.N. Schaid, D. John, E.M. Maier, C. Vogel, W. Cooney, K.A. Park, J.Y. Cannon-Albright, L. Brenner, H. Habuchi, T. Zhang, H.-. Lu, Y.-. Kaneva, R. Muir, K. Benlloch, S. Leongamornlert, D.A. Saunders, E.J. Tymrakiewicz, M. Mahmud, N. Guy, M. O'Brien, L.T. Wilkinson, R.A. Hall, A.L. Sawyer, E.J. Dadaev, T. Morrison, J. Dearnaley, D.P. Horwich, A. Huddart, R.A. Khoo, V.S. Parker, C.C. Van As, N. Woodhouse, C.J. Thompson, A. Christmas, T. Ogden, C. Cooper, C.S. Lophatonanon, A. Southey, M.C. Hopper, J.L. English, D.R. Wahlfors, T. Tammela, T.L. Klarskov, P. Nordestgaard, B.G. Røder, M.A. Tybjærg-Hansen, A. Bojesen, S.E. Travis, R. Canzian, F. Kaaks, R. Wiklund, F. Aly, M. Lindstrom, S. Diver, W.R. Gapstur, S. Stern, M.C. Corral, R. Virtamo, J. Cox, A. Haiman, C.A. Le Marchand, L. Fitzgerald, L. Kolb, S. Kwon, E.M. Karyadi, D.M. Orntoft, T.F. Borre, M. Meyer, A. Serth, J. Yeager, M. Berndt, S.I. Marthick, J.R. Patterson, B. Wokolorczyk, D. Batra, J. Lose, F. McDonnell, S.K. Joshi, A.D. Shahabi, A. Rinckleb, A.E. Ray, A. Sellers, T.A. Lin, H.-. Stephenson, R.A. Farnham, J. Muller, H. Rothenbacher, D. Tsuchiya, N. Narita, S. Cao, G.-. Slavov, C. Mitev, V. Easton, D.F. Eeles, R.A. UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource, PRACTICAL Consortium, (2011). Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat genet, Vol.43 (8), pp. 785-791.  show abstract

Warde, P. Huddart, R. Bolton, D. Heidenreich, A. Gilligan, T. Fossa, S. (2011). Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology, Vol.78 (4 Suppl), pp. S435-S443.  show abstract

Huddart, R.A. Gabe, R. Cafferty, F. Pollock, P. White, J.D. Shamash, J. Stenning, S.P. Collabor, T.T. Studies, N.C. (2011). A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604). Journal of clinical oncology, Vol.29 (15).

Huddart, R.A. Gabe, R. Cafferty, F. Pollock, P. White, J.D. Shamash, J. Stenning, S.P. TE23 Trial Management Group and Collaborators, NCRI Testis Cancer Clinical Studies Group, (2011). A randomized phase II trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor prognosis germ cell tumors (MRC TE23, CRUK 05/014, ISRCTN53643604). J clin oncol, Vol.29 (15_suppl), p. 4508.  show abstract

Maroto, P. Huddart, R. Garcia del Muro, X. Horwich, A. Paz Ares, L. Aparicio, J. Germa-Lluch, J.R. (2011). Brief report: phase II multicenter study of temozolomide in patients with cisplatin-resistant germ cell tumors. Oncology, Vol.80 (3-4), pp. 219-222.  show abstract

MacInnis, R.J. Antoniou, A.C. Eeles, R.A. Severi, G. Guy, M. McGuffog, L. Hall, A.L. O'Brien, L.T. Wilkinson, R.A. Dearnaley, D.P. Ardern-Jones, A.T. Horwich, A. Khoo, V.S. Parker, C.C. Huddart, R.A. McCredie, M.R. Smith, C. Southey, M.C. Staples, M.P. English, D.R. Hopper, J.L. Giles, G.G. Easton, D.F. (2010). Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies. Genet epidemiol, Vol.34 (1), pp. 42-50.  show abstract

Vergis, R. Corbishley, C.M. Thomas, K. Horwich, A. Huddart, R. Khoo, V. Eeles, R. Sydes, M.R. Cooper, C.S. Dearnaley, D. Parker, C. (2010). Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. Int j radiat oncol biol phys, Vol.78 (1), pp. 35-41.  show abstract

Huddart, R.A. (2010). Stage I germ cell tumours: achieving cure at minimal cost. Clin oncol (r coll radiol), Vol.22 (1), pp. 1-5.

Venkitaraman, R. Sohaib, S.A. Barbachano, Y. Parker, C.C. Huddart, R.A. Horwich, A. Dearnaley, D. (2010). Frequency of screening magnetic resonance imaging to detect occult spinal cord compromise and to prevent neurological deficit in metastatic castration-resistant prostate cancer. Clin oncol (r coll radiol), Vol.22 (2), pp. 147-152.  show abstract

Venkitaraman, R. Thomas, K. Grace, P. Dearnaley, D.P. Horwich, A. Huddart, R.A. Parker, C.C. (2010). Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance. Tumour biol, Vol.31 (2), pp. 97-102.  show abstract

Guerrero Urbano, T. Khoo, V. Staffurth, J. Norman, A. Buffa, F. Jackson, A. Adams, E. Hansen, V. Clark, C. Miles, E. McNair, H. Nutting, C. Parker, C. Eeles, R. Huddart, R. Horwich, A. Dearnaley, D.P. (2010). Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. Clin oncol (r coll radiol), Vol.22 (3), pp. 236-244.  show abstract

Cummins, S. Yau, T. Huddart, R. Dearnaley, D. Horwich, A. (2010). Surveillance in stage I seminoma patients: a long-term assessment. Eur urol, Vol.57 (4), pp. 673-678.  show abstract

Wood, L. Kollmannsberger, C. Jewett, M. Chung, P. Hotte, S. O'Malley, M. Sweet, J. Anson-Cartwright, L. Winquist, E. North, S. Tyldesley, S. Sturgeon, J. Gospodarowicz, M. Segal, R. Cheng, T. Venner, P. Moore, M. Albers, P. Huddart, R. Nichols, C. Warde, P. (2010). Canadian consensus guidelines for the management of testicular germ cell cancer. Can urol assoc j, Vol.4 (2), pp. e19-e38.

Schmoll, H.-. Jordan, K. Huddart, R. Pes, M.P. Horwich, A. Fizazi, K. Kataja, V. ESMO Guidelines Working Group, (2010). Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol, Vol.21 Suppl 5, pp. v147-v154.

Schmoll, H.-. Jordan, K. Huddart, R. Pes, M.P. Horwich, A. Fizazi, K. Kataja, V. ESMO Guidelines Working Group, (2010). Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol, Vol.21 Suppl 5, pp. v140-v146.

Huddart, R.A. (2010). Stage I Germ Cell Tumours: Achieving Cure at Minimal Cost. Clin oncol-uk, Vol.22 (5), pp. 392-392.

Turnbull, C. Rapley, E.A. Seal, S. Pernet, D. Renwick, A. Hughes, D. Ricketts, M. Linger, R. Nsengimana, J. Deloukas, P. Huddart, R.A. Bishop, D.T. Easton, D.F. Stratton, M.R. Rahman, N. UK Testicular Cancer Collaboration, (2010). Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat genet, Vol.42 (7), pp. 604-607.  show abstract

Mai, P.L. Friedlander, M. Tucker, K. Phillips, K.-. Hogg, D. Jewett, M.A. Lohynska, R. Daugaard, G. Richard, S. Bonaïti-Pellié, C. Heidenreich, A. Albers, P. Bodrogi, I. Geczi, L. Olah, E. Daly, P.A. Guilford, P. Fosså, S.D. Heimdal, K. Liubchenko, L. Tjulandin, S.A. Stoll, H. Weber, W. Easton, D.F. Dudakia, D. Huddart, R. Stratton, M.R. Einhorn, L. Korde, L. Nathanson, K.L. Bishop, D.T. Rapley, E.A. Greene, M.H. (2010). The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. Urol oncol, Vol.28 (5), pp. 492-499.  show abstract

Teoh, E.M. Dearnaley, D.P. Horwich, A. Van As, N. Riley, U. Huddart, R.A. (2010). The efficacy of preventing neutropenic sepsis in patients with testicular germ cell tumours: results of two consecutive audits. Clin oncol (r coll radiol), Vol.22 (10), pp. 891-892.

Glendenning, J.L. Barbachano, Y. Norman, A.R. Dearnaley, D.P. Horwich, A. Huddart, R.A. (2010). Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer, Vol.116 (10), pp. 2322-2331.  show abstract

Gilbert, D.C. McIntyre, A. Summersgill, B. Missiaglia, E. Goddard, N.C. Chandler, I. Huddart, R.A. Shipley, J. (2010). Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes chromosomes cancer, .  show abstract

Gilbert, D.C. Chandler, I. McIntyre, A. Goddard, N.C. Gabe, R. Huddart, R.A. Shipley, J. (2009). Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumours of adults and adolescents. J pathol, Vol.217 (1), pp. 94-102.  show abstract

Guy, M. Kote-Jarai, Z. Giles, G.G. Al Olama, A.A. Jugurnauth, S.K. Mulholland, S. Leongamornlert, D.A. Edwards, S.M. Morrison, J. Field, H.I. Southey, M.C. Severi, G. Donovan, J.L. Hamdy, F.C. Dearnaley, D.P. Muir, K.R. Smith, C. Bagnato, M. Ardern-Jones, A.T. Hall, A.L. O'Brien, L.T. Gehr-Swain, B.N. Wilkinson, R.A. Cox, A. Lewis, S. Brown, P.M. Jhavar, S.G. Tymrakiewicz, M. Lophatananon, A. Bryant, S.L. UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, Horwich, A. Huddart, R.A. Khoo, V.S. Parker, C.C. Woodhouse, C.J. Thompson, A. Christmas, T. Ogden, C. Fisher, C. Jameson, C. Cooper, C.S. English, D.R. Hopper, J.L. Neal, D.E. Easton, D.F. Eeles, R.A. (2009). Identification of new genetic risk factors for prostate cancer. Asian j androl, Vol.11 (1), pp. 49-55.  show abstract

Moynihan, C. Norman, A.R. Barbachano, Y. Burchell, L. Huddart, R. Dearnaley, D.P. Horwich, A. (2009). Prospective study of factors predicting adherence to medical advice in men with testicular cancer. J clin oncol, Vol.27 (13), pp. 2144-2150.  show abstract

Venkitaraman, R. Cook, G.J. Dearnaley, D.P. Parker, C.C. Huddart, R.A. Khoo, V. Eeles, R. Horwich, A. Sohaib, S.A. (2009). Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer?. Clin oncol (r coll radiol), Vol.21 (1), pp. 39-42.  show abstract

Gilbert, D.C. Van As, N.J. Huddart, R.A. (2009). Reducing treatment toxicities in the management of good prognosis testicular germ cell tumors. Expert rev anticancer ther, Vol.9 (2), pp. 223-233.  show abstract

Lalondrelle, S. McNair, H. Hansen, V. Huddart, R. Dearnaley, D. Khoo, V. (2009). The Clinical Implementation of Cone Beam CT (CBCT) Technology through Adaptive Radiotherapy Planning (ART). Clin oncol-uk, Vol.21 (1), pp. 67-67.

Sohaib, S.A. Koh, D.M. Barbachano, Y. Parikh, J. Husband, J.E. Dearnaley, D.P. Horwich, A. Huddart, R. (2009). Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin radiol, Vol.64 (4), pp. 362-367.  show abstract

Ng, M.K. Van As, N. Thomas, K. Woode-Amissah, R. Horwich, A. Huddart, R. Khoo, V. Thompson, A. Dearnaley, D. Parker, C. (2009). Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling time. Bju int, Vol.103 (7), pp. 872-876.  show abstract

Lalondrelle, S. Taylor, H. McNair, H. Hansen, V.N. Huddart, R. Khoo, V. (2009). Steps to Clinical Implementation of Online Image Guided Adaptive Radiotherapy. Clin oncol-uk, Vol.21 (3), pp. 256-256.

Schmoll, H.-. Jordan, K. Huddart, R. Laguna, M.P. Horwich, A. Fizazi, K. Kataja, V. ESMO Guidelines Working Group, (2009). Testicular non-seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann oncol, Vol.20 Suppl 4, pp. 89-96.

Schmoll, H.-. Jordan, K. Huddart, R. Laguna, M.P. Horwich, A. Fizazi, K. Kataja, V. ESMO Guidelines Working Group, (2009). Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann oncol, Vol.20 Suppl 4, pp. 83-88.

Highley, M.S. Griffiths, G.O. Uscinska, B.M. Huddart, R.A. Barber, J.B. Parmar, M.K. Harper, P.G. NCRI Bladder Cancer Clinical Studies Group, (2009). A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract. Clin oncol (r coll radiol), Vol.21 (5), pp. 394-400.  show abstract

Zaidi, S.H. Huddart, R.A. Harrington, K.J. (2009). Novel targeted radiosensitisers in cancer treatment. Curr drug discov technol, Vol.6 (2), pp. 103-134.  show abstract

Venkitaraman, R. Cook, G.J. Dearnaley, D.P. Parker, C.C. Khoo, V. Eeles, R. Huddart, R.A. Horwich, A. Sohaib, S.A. (2009). Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J med imaging radiat oncol, Vol.53 (3), pp. 241-247.  show abstract

Venkitaraman, R. Cook, G.J. Dearnaley, D.P. Parker, C.C. Khoo, V. Eeles, R. Huddart, R.A. Horwich, A. Sohaib, S.A. (2009). Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J med imag radiat on, Vol.53 (3), pp. 241-247.  show abstract

Lalondrelle, S. Huddart, R. (2009). Improving radiotherapy for bladder cancer: an opportunity to integrate new technologies. Clin oncol (r coll radiol), Vol.21 (5), pp. 380-384.

Rapley, E.A. Turnbull, C. Al Olama, A.A. Dermitzakis, E.T. Linger, R. Huddart, R.A. Renwick, A. Hughes, D. Hines, S. Seal, S. Morrison, J. Nsengimana, J. Deloukas, P. UK Testicular Cancer Collaboration, Rahman, N. Bishop, D.T. Easton, D.F. Stratton, M.R. (2009). A genome-wide association study of testicular germ cell tumor. Nat genet, Vol.41 (7), pp. 807-810.  show abstract

Al Olama, A.A. Kote-Jarai, Z. Giles, G.G. Guy, M. Morrison, J. Severi, G. Leongamornlert, D.A. Tymrakiewicz, M. Jhavar, S. Saunders, E. Hopper, J.L. Southey, M.C. Muir, K.R. English, D.R. Dearnaley, D.P. Ardern-Jones, A.T. Hall, A.L. O'Brien, L.T. Wilkinson, R.A. Sawyer, E. Lophatananon, A. UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators, Horwich, A. Huddart, R.A. Khoo, V.S. Parker, C.C. Woodhouse, C.J. Thompson, A. Christmas, T. Ogden, C. Cooper, C. Donovan, J.L. Hamdy, F.C. Neal, D.E. Eeles, R.A. Easton, D.F. (2009). Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat genet, Vol.41 (10), pp. 1058-1060.  show abstract

Eeles, R.A. Kote-Jarai, Z. Al Olama, A.A. Giles, G.G. Guy, M. Severi, G. Muir, K. Hopper, J.L. Henderson, B.E. Haiman, C.A. Schleutker, J. Hamdy, F.C. Neal, D.E. Donovan, J.L. Stanford, J.L. Ostrander, E.A. Ingles, S.A. John, E.M. Thibodeau, S.N. Schaid, D. Park, J.Y. Spurdle, A. Clements, J. Dickinson, J.L. Maier, C. Vogel, W. Dörk, T. Rebbeck, T.R. Cooney, K.A. Cannon-Albright, L. Chappuis, P.O. Hutter, P. Zeegers, M. Kaneva, R. Zhang, H.-. Lu, Y.-. Foulkes, W.D. English, D.R. Leongamornlert, D.A. Tymrakiewicz, M. Morrison, J. Ardern-Jones, A.T. Hall, A.L. O'Brien, L.T. Wilkinson, R.A. Saunders, E.J. Page, E.C. Sawyer, E.J. Edwards, S.M. Dearnaley, D.P. Horwich, A. Huddart, R.A. Khoo, V.S. Parker, C.C. Van As, N. Woodhouse, C.J. Thompson, A. Christmas, T. Ogden, C. Cooper, C.S. Southey, M.C. Lophatananon, A. Liu, J.-. Kolonel, L.N. Le Marchand, L. Wahlfors, T. Tammela, T.L. Auvinen, A. Lewis, S.J. Cox, A. FitzGerald, L.M. Koopmeiners, J.S. Karyadi, D.M. Kwon, E.M. Stern, M.C. Corral, R. Joshi, A.D. Shahabi, A. McDonnell, S.K. Sellers, T.A. Pow-Sang, J. Chambers, S. Aitken, J. Gardiner, R.A. Batra, J. Kedda, M.A. Lose, F. Polanowski, A. Patterson, B. Serth, J. Meyer, A. Luedeke, M. Stefflova, K. Ray, A.M. Lange, E.M. Farnham, J. Khan, H. Slavov, C. Mitkova, A. Cao, G. UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, PRACTICAL Consortium, Easton, D.F. (2009). Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat genet, Vol.41 (10), pp. 1116-1121.  show abstract

Gilbert, D.C. Vanas, N.J. Beesley, S. Bloomfield, D. Money-Kyrle, J. Norman, A. Dearnaley, D. Horwich, A. Huddart, R.A. (2009). Treating IIA/B seminoma with combination carboplatin and radiotherapy. J clin oncol, Vol.27 (12), pp. 2101-2102.

Moynihan, C. Hall, E. Lewis, R. Birtle, A. Mead, G.M. Huddart, R. SPARE Trial Management Group, (2009). SPARE: A qualitative study investigating randomization barriers in a Selective Bladder Preservation trial (SBP) (ISCRCTN: 61126465). J clin oncol, Vol.27 (15_suppl), p. 5077.  show abstract

McVey, G.P. Morgan, S.C. Vergis, R. Corbishley, C. Thomas, K. Cooper, C. Horwich, A. Huddart, R. Dearnaley, D.P. Parker, C.C. (2009). Benefit of radiotherapy dose escalation in localized prostate cancer with respect to expression of intrinsic markers of hypoxia. J clin oncol, Vol.27 (15_suppl), p. e16068.  show abstract

Wheater, M.J. Huddart, R. White, J. Rustin, G. Abab, J. Mead, G.M. (2009). Salvage chemotherapy with gemcitabine, paclitaxel, ifosphamide, and cisplatin (Gem-TIP) for relapsed germ cell tumours (GCT). J clin oncol, Vol.27 (15_suppl), p. e16031.  show abstract

Huddart, R.A. James, N.D. Adab, F. Syndikus, I. Jenkins, P. Rawlings, C. Hendron, C. Lewis, R. Rogers, S. Hall, E. BC2001 Investigators, (2009). BC2001: A multicenter phase III randomized trial of standard versus reduced volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339). J clin oncol, Vol.27 (15_suppl), p. 5022.  show abstract

Harland, S.J. Welch, R. Huddart, R. Stenning, S. Pollock, P. Gabe, R. (2009). On the necessity for postchemotherapy surgery for residual abdominal masses in metastatic nonseminomatous germ cell tumors (NSGCT) of testis. J clin oncol, Vol.27 (15_suppl), p. 5088.  show abstract

Jhavar, S. Bartlett, J. Kovacs, G. Corbishley, C. Dearnaley, D. Eeles, R. Khoo, V. Huddart, R. Horwich, A. Thompson, A. Norman, A. Brewer, D. Cooper, C.S. Parker, C. (2009). Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate cancer prostatic dis, Vol.12 (2), pp. 143-147.  show abstract

Mai, P.L. Chen, B.E. Tucker, K. Friedlander, M. Phillips, K.-. Hogg, D. Jewett, M.A. Bodrogi, I. Geczi, L. Olah, E. Heimdal, K. Fosså, S.D. Nathanson, K.L. Korde, L. Easton, D.F. Dudakia, D. Huddart, R. Stratton, M.R. Bishop, D.T. Rapley, E.A. Greene, M.H. (2009). Younger age-at-diagnosis for familial malignant testicular germ cell tumor. Fam cancer, Vol.8 (4), pp. 451-456.  show abstract

Venkitaraman, R. Norman, A. Woode-Amissah, R. Dearnaley, D. Horwich, A. Huddart, R. Parker, C. (2008). Prostate-specific antigen velocity in untreated, localized prostate cancer. Bju int, Vol.101 (2), pp. 161-164.  show abstract

Coffey, J. Linger, R. Pugh, J. Dudakia, D. Sokal, M. Easton, D.F. Timothy Bishop, D. Stratton, M. Huddart, R. Rapley, E.A. (2008). Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes chromosomes cancer, Vol.47 (1), pp. 34-42.  show abstract

Venkitaraman, R. Thomas, K. Huddart, R.A. Horwich, A. Dearnaley, D.P. Parker, C.C. (2008). Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. Bju int, Vol.101 (4), pp. 440-443.  show abstract

Huddart, R.A. (2008). The management of non-seminomatous germ-cell tumours patients with viable malignancy at the time of RPLND. Ann oncol, Vol.19 (2), pp. 203-204.

Eeles, R.A. Kote-Jarai, Z. Giles, G.G. Olama, A.A. Guy, M. Jugurnauth, S.K. Mulholland, S. Leongamornlert, D.A. Edwards, S.M. Morrison, J. Field, H.I. Southey, M.C. Severi, G. Donovan, J.L. Hamdy, F.C. Dearnaley, D.P. Muir, K.R. Smith, C. Bagnato, M. Ardern-Jones, A.T. Hall, A.L. O'Brien, L.T. Gehr-Swain, B.N. Wilkinson, R.A. Cox, A. Lewis, S. Brown, P.M. Jhavar, S.G. Tymrakiewicz, M. Lophatananon, A. Bryant, S.L. UK Genetic Prostate Cancer Study Collaborators, British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, Horwich, A. Huddart, R.A. Khoo, V.S. Parker, C.C. Woodhouse, C.J. Thompson, A. Christmas, T. Ogden, C. Fisher, C. Jamieson, C. Cooper, C.S. English, D.R. Hopper, J.L. Neal, D.E. Easton, D.F. (2008). Multiple newly identified loci associated with prostate cancer susceptibility. Nat genet, Vol.40 (3), pp. 316-321.  show abstract

Krege, S. Beyer, J. Souchon, R. Albers, P. Albrecht, W. Algaba, F. Bamberg, M. Bodrogi, I. Bokemeyer, C. Cavallin-Ståhl, E. Classen, J. Clemm, C. Cohn-Cedermark, G. Culine, S. Daugaard, G. De Mulder, P.H. De Santis, M. de Wit, M. de Wit, R. Derigs, H.G. Dieckmann, K.-. Dieing, A. Droz, J.-. Fenner, M. Fizazi, K. Flechon, A. Fosså, S.D. del Muro, X.G. Gauler, T. Geczi, L. Gerl, A. Germa-Lluch, J.R. Gillessen, S. Hartmann, J.T. Hartmann, M. Heidenreich, A. Hoeltl, W. Horwich, A. Huddart, R. Jewett, M. Joffe, J. Jones, W.G. Kisbenedek, L. Klepp, O. Kliesch, S. Koehrmann, K.U. Kollmannsberger, C. Kuczyk, M. Laguna, P. Galvis, O.L. Loy, V. Mason, M.D. Mead, G.M. Mueller, R. Nichols, C. Nicolai, N. Oliver, T. Ondrus, D. Oosterhof, G.O. Ares, L.P. Pizzocaro, G. Pont, J. Pottek, T. Powles, T. Rick, O. Rosti, G. Salvioni, R. Scheiderbauer, J. Schmelz, H.-. Schmidberger, H. Schmoll, H.-. Schrader, M. Sedlmayer, F. Skakkebaek, N.E. Sohaib, A. Tjulandin, S. Warde, P. Weinknecht, S. Weissbach, L. Wittekind, C. Winter, E. Wood, L. von der Maase, H. (2008). European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur urol, Vol.53 (3), pp. 478-496.  show abstract

Krege, S. Beyer, J. Souchon, R. Albers, P. Albrecht, W. Algaba, F. Bamberg, M. Bodrogi, I. Bokemeyer, C. Cavallin-Ståhl, E. Classen, J. Clemm, C. Cohn-Cedermark, G. Culine, S. Daugaard, G. De Mulder, P.H. De Santis, M. de Wit, M. de Wit, R. Derigs, H.G. Dieckmann, K.-. Dieing, A. Droz, J.-. Fenner, M. Fizazi, K. Flechon, A. Fosså, S.D. del Muro, X.G. Gauler, T. Geczi, L. Gerl, A. Germa-Lluch, J.R. Gillessen, S. Hartmann, J.T. Hartmann, M. Heidenreich, A. Hoeltl, W. Horwich, A. Huddart, R. Jewett, M. Joffe, J. Jones, W.G. Kisbenedek, L. Klepp, O. Kliesch, S. Koehrmann, K.U. Kollmannsberger, C. Kuczyk, M. Laguna, P. Galvis, O.L. Loy, V. Mason, M.D. Mead, G.M. Mueller, R. Nichols, C. Nicolai, N. Oliver, T. Ondrus, D. Oosterhof, G.O. Paz-Ares, L. Pizzocaro, G. Pont, J. Pottek, T. Powles, T. Rick, O. Rosti, G. Salvioni, R. Scheiderbauer, J. Schmelz, H.-. Schmidberger, H. Schmoll, H.-. Schrader, M. Sedlmayer, F. Skakkebaek, N.E. Sohaib, A. Tjulandin, S. Warde, P. Weinknecht, S. Weissbach, L. Wittekind, C. Winter, E. Wood, L. von der Maase, H. (2008). European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur urol, Vol.53 (3), pp. 497-513.  show abstract

Linger, R. Dudakia, D. Huddart, R. Tucker, K. Friedlander, M. Phillips, K.-. Hogg, D. Jewett, M.A. Lohynska, R. Daugaard, G. Richard, S. Chompret, A. Stoppa-Lyonnet, D. Bonaïti-Pellié, C. Heidenreich, A. Albers, P. Olah, E. Geczi, L. Bodrogi, I. Daly, P.A. Guilford, P. Fosså, S.D. Heimdal, K. Tjulandin, S.A. Liubchenko, L. Stoll, H. Weber, W. Einhorn, L. McMaster, M. Korde, L. Greene, M.H. Nathanson, K.L. Cortessis, V. Easton, D.F. Bishop, D.T. Stratton, M.R. Rapley, E.A. (2008). Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. Genes chromosomes cancer, Vol.47 (3), pp. 247-252.  show abstract

Linger, R. Dudakia, D. Huddart, R. Tucker, K. Friedlander, M. Phillips, K.A. Hogg, D. Jewett, M.A. Lohynska, R. Daugaard, G. Richard, S. Chompret, A. Stoppa-Lyonnet, D. Bonaiti-Pellie, C. Heidenreich, A. Albers, P. Olah, E. Geczi, L. Bodrogi, I. Daly, P.A. Guilford, P. Fossi, S.D. Heimdal, K. Tjulandin, S.A. Liubchenko, L. Stoll, H. Weber, W. Einhorn, L. McMaster, M. Korde, L. Greene, M.H. Nathanson, K.L. Cortessis, V. Easton, D.F. Bishop, D.T. Stratton, M.R. Rapley, E.A. (2008). Analysis of the DNDI gene in men with sporadic and familial testicular germ cell tumors. Gene chromosome canc, Vol.47 (3), pp. 247-252.  show abstract

Vergis, R. Corbishley, C.M. Norman, A.R. Bartlett, J. Jhavar, S. Borre, M. Heeboll, S. Horwich, A. Huddart, R. Khoo, V. Eeles, R. Cooper, C. Sydes, M. Dearnaley, D. Parker, C. (2008). Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet oncol, Vol.9 (4), pp. 342-351.  show abstract

Venkitaraman, R. Price, A. Coffey, J. Norman, A.R. James, F.V. Huddart, R.A. Horwich, A. Dearnaley, D.P. (2008). Pentoxifylline to treat radiation proctitis: a small and inconclusive randomised trial. Clin oncol (r coll radiol), Vol.20 (4), pp. 288-292.  show abstract

Huddart, R. Kataja, V. ESMO Guidelines Working Group, (2008). Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann oncol, Vol.19 Suppl 2, pp. ii49-ii51.

Huddart, R. Kataja, V. ESMO Guidelines Working Group, (2008). Mixed or non-seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann oncol, Vol.19 Suppl 2, pp. ii52-ii54.

Venkitaraman, R. Price, A. Coffey, J. Norman, A.R. James, F.V. Huddart, R.A. Horwich, A. Dearnaley, D.P. (2008). Pentoxifylline to treat radiation proctitis: A small and inconclusive randomised trial (vol 20, pg 288, 2008). Clin oncol-uk, Vol.20 (5), pp. 386-386.

Venkitaraman, R. Thomas, K. Grace, P. Dearnaley, D. Horwich, A. Huddart, R. Parker, C.C. (2008). Baseline urinary phytoestrogen levels and the natural history of untreated, localised prostate cancer in a British population. Int j biol markers, Vol.23 (3), pp. 192-197.  show abstract

Krege, S. Beyer, J. Souchon, R. Albers, P. Albrecht, W. Algaba, F. Bamberg, M. Bodrogi, I. Bokemeyer, C. Cavallin-Stahl, E. Classen, J. Clemm, C. Cohn-Cedermark, G. Culine, S. Daugaard, G. De Mulder, P.H. De Santis, M. de Wit, M. de Wit, R. Derigs, H.G. Dieckmann, K.P. Dieing, A. Droz, J.P. Fenner, M. Fizazi, K. Flechon, A. Fossa, S.D. del Muro, X.G. Gauler, T. Geczi, L. Gerl, A. Germa-Lluch, J.R. Gillessen, S. Hartmann, J.T. Hartmann, M. Heidenreich, A. Hoeltl, W. Horwich, A. Huddart, R. Jewett, M. Joffe, J. Jones, W.G. Kisbenedek, L. Klepp, O. Kliesch, S. Koehrmann, K.U. Kollmannsberger, C. Kuczyk, M. Laguna, P. Galvis, O.L. Loy, V. Mason, M.D. Mead, G.M. Mueller, R. Nichols, C. Nicolai, N. Oliver, T. Ondrus, D. Oosterhof, G.O. Ares, L.P. Pizzocaro, G. Pont, J. Pottek, T. Powles, T. Rick, O. Rosti, G. Salvioni, R. Scheiderbauer, J. Schmelz, H.U. Schmidberger, H. Schmoll, H.J. Schrader, M. Sedlmayer, F. Skakkebaek, N.E. Sohaib, A. Tjulandin, S. Warde, P. Weinknecht, S. Weissbach, L. Wittekind, C. Winter, E. Wood, L. von der Maase, H. (2008). European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European germ cell cancer consensus group (EGCCCG): Part 1 (vol 53, pg 478, 2008). Eur urol, Vol.54 (2), pp. 480-480.

Krege, S. Beyer, J. Souchon, R. Albers, P. Albrecht, W. Algaba, F. Bamberg, M. Bodrogi, I. Bokemeyer, C. Cavallin-Stahl, E. Classen, J. Clemm, C. Cohn-Cedermark, G. Culine, S. Daugaard, G. De Mulder, P.H. De Santis, M. de Wit, M. de Wit, R. Derigs, H.G. Dieckmann, K.P. Dieing, A. Droz, J.P. Fenner, M. Fizazi, K. Flechon, A. Fossa, S.D. del Muro, X.G. Gauler, T. Geczi, L. Gerl, A. Germa-Lluch, J.R. Gillessen, S. Hartmann, J.T. Hartmann, M. Heidenreich, A. Hoeltl, W. Horwich, A. Huddart, R. Jewett, M. Joffe, J. Jones, W.G. Kisbenedek, L. Klepp, O. Kliesch, S. Koehrmann, K.U. Kollmannsberger, C. Kuczyk, M. Laguna, P. Galvis, O.L. Loy, V. Mason, M.D. Mead, G.M. Mueller, R. Nichols, C. Nicolai, N. Oliver, T. Ondrus, D. Oosterhof, G.O. Ares, L.P. Pizzocaro, G. Pont, J. Pottek, T. Powles, T. Rick, O. Rosti, G. Salvioni, R. Scheiderbauer, J. Schmelz, H.U. Schmidberger, H. Schmoll, H.J. Schrader, M. Sedlmayer, F. Skakkebaek, N.E. Sohaib, A. Tjulandin, S. Warde, P. Weinknecht, S. Weissbach, L. Wittekind, C. Winter, E. Wood, L. von der Maase, H. (2008). European consensus conference on diagnosis and treatment of germ cell cancer: A report of the second meeting of the European germ cell cancer consensus group (EGCCCG): Part II (vol 53, pg 497, 2008). Eur urol, Vol.54 (2), pp. 480-480.

Mangar, S.A. Miller, N.R. Khoo, V.S. Hansen, V. McNair, H. Horwich, A. Huddart, R.A. (2008). Evaluating inter-fractional changes in volume and position during bladder radiotherapy and the effect of volume limitation as a method of reducing the internal margin of the planning target volume. Clin oncol (r coll radiol), Vol.20 (9), pp. 698-704.  show abstract

van As, N.J. Norman, A.R. Thomas, K. Khoo, V.S. Thompson, A. Huddart, R.A. Horwich, A. Dearnaley, D.P. Parker, C.C. (2008). Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur urol, Vol.54 (6), pp. 1297-1305.  show abstract

van As, N.J. Gilbert, D.C. Money-Kyrle, J. Bloomfield, D. Beesley, S. Dearnaley, D.P. Horwich, A. Huddart, R.A. (2008). Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br j cancer, Vol.98 (12), pp. 1894-1902.  show abstract

Huddart, R.A. (2008). Survival from testicular cancer in England and Wales up to 2001. Br j cancer, Vol.99 Suppl 1, pp. S83-S85.

Venkitaraman, R. Norman, A.R. Iqbal, J. Dearnaley, D.P. Horwich, A. Huddart, R.A. Parker, C.C. (2008). Clinical implications of introducing a new PSA assay. Int urol nephrol, Vol.40 (3), pp. 657-661.  show abstract

Hafeez, S. Sharma, R.A. Huddart, R.A. Dearnaley, D.P. Horwich, A. (2007). Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience. Clin oncol (r coll radiol), Vol.19 (2), pp. 135-142.  show abstract

Dearnaley, D.P. Sydes, M.R. Langley, R.E. Graham, J.D. Huddart, R.A. Syndikus, I. Matthews, J.H. Scrase, C.D. Jose, C.C. Logue, J. Stephens, R.J. RT01 Collaborators, (2007). The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397). Radiother oncol, Vol.83 (1), pp. 31-41.  show abstract

ESMO Guidelines Working Group, Huddart, R.A. (2007). Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann oncol, Vol.18 Suppl 2, pp. ii40-ii41.

ESMO Guidelines Working Group, Huddart, R.A. (2007). Mixed or non-seminomatous germ-cell tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann oncol, Vol.18 Suppl 2, pp. ii42-ii43.

Mangar, S.A. Mitter, N.A. Norman, A. Hansen, V. Foo, K. McNair, H. Horwich, A. Huddart, R.A. (2007). Evaluating the impact of volume limitation as a method of reducing the internal margin of the PTV in bladder radiotherapy. Clin oncol-uk, Vol.19 (3), pp. S38-S39.

Dearnaley, D.P. Sydes, M.R. Langley, R.E. Graham, J.D. Huddart, R.A. Syndikus, I. Matthews, J.H. Scrase, C.D. Jose, C.C. Logue, J. Stephens, R.J. (2007). The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397). Radiother oncol, Vol.83 (1), pp. 31-41.  show abstract

Mangar, S. Thompson, A. Miles, E. Huddart, R. Horwich, A. Khoo, V. (2007). A feasibility study of using gold seeds as fiducial markers for bladder localization during radical radiotherapy. Br j radiol, Vol.80 (952), pp. 279-283.  show abstract

Dearnaley, D.P. Sydes, M.R. Graham, J.D. Aird, E.G. Bottomley, D. Cowan, R.A. Huddart, R.A. Jose, C.C. Matthews, J.H. Millar, J. Moore, A.R. Morgan, R.C. Russell, J.M. Scrase, C.D. Stephens, R.J. Syndikus, I. Parmar, M.K. RT01 collaborators, (2007). Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet oncol, Vol.8 (6), pp. 475-487.  show abstract

Dearnaley, D.P. Sydes, M.R. Graham, J.D. Aird, E.G. Bottomley, D. Cowan, R.A. Huddart, R.A. Jose, C.C. Matthews, J.H. Millar, J. Moore, A.R. Morgan, R.C. Russell, J.M. Scrase, C.D. Stephens, R.J. Syndikus, I. Parmar, M.K. RT01 Collaborators, (2007). Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet oncol, Vol.8 (6), pp. 475-487.  show abstract

Venkitaraman, R. Johnson, B. Huddart, R.A. Parker, C.C. Horwich, A. Dearnaley, D.P. (2007). The utility of lactate dehydrogenase in the follow-up of testicular germ cell tumours. Bju int, Vol.100 (1), pp. 30-32.  show abstract

Venkitaraman, R. Sohaib, S.A. Barbachano, Y. Parker, C.C. Khoo, V. Huddart, R.A. Horwich, A. Dearnaley, D.P. (2007). Detection of occult spinal cord compression with magnetic resonance imaging of the spine. Clin oncol (r coll radiol), Vol.19 (7), pp. 528-531.  show abstract

Venkitaraman, R. Norman, A. Woode-Amissah, R. Fisher, C. Dearnaley, D. Horwich, A. Huddart, R. Khoo, V. Thompson, A. Parker, C. (2007). Predictors of histological disease progression in untreated, localized prostate cancer. J urol, Vol.178 (3 Pt 1), pp. 833-837.  show abstract

Rustin, G.J. Mead, G.M. Stenning, S.P. Vasey, P.A. Aass, N. Huddart, R.A. Sokal, M.P. Joffe, J.K. Harland, S.J. Kirk, S.J. National Cancer Research Institute Testis Cancer Clinical Studies Group, (2007). Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J clin oncol, Vol.25 (11), pp. 1310-1315.  show abstract

Mangar, S.A. Scurr, E. Huddart, R.A. Sohaib, S.A. Horwich, A. Dearnaley, D.P. Khoo, V.S. (2007). Assessing intra-fractional bladder motion using cine-MRI as initial methodology for Predictive Organ Localization (POLO) in radiotherapy for bladder cancer. Radiother oncol, Vol.85 (2), pp. 207-214.  show abstract

Venkitaraman, R. Barbachano, Y. Dearnaley, D.P. Parker, C.C. Khoo, V. Huddart, R.A. Eeles, R. Horwich, A. Sohaib, S.A. (2007). Outcome of early detection and radiotherapy for occult spinal cord compression. Radiother oncol, Vol.85 (3), pp. 469-472.  show abstract

Mason, M.D. Sydes, M.R. Glaholm, J. Langley, R.E. Huddart, R.A. Sokal, M. Stott, M. Robinson, A.C. James, N.D. Parmar, M.K. Dearnaley, D.P. Medical Research Council PR04 Collaborators, (2007). Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J natl cancer inst, Vol.99 (10), pp. 765-776.  show abstract

Coffey, J. Huddart, R.A. Elliott, F. Sohaib, S.A. Parker, E. Dudakia, D. Pugh, J.L. Easton, D.F. Bishop, D.T. Stratton, M.R. Rapley, E.A. (2007). Testicular microlithiasis as a familial risk factor for testicular germ cell tumour. Br j cancer, Vol.97 (12), pp. 1701-1706.  show abstract

Huddart, R.A. O'Doherty, M.J. Padhani, A. Rustin, G.J. Mead, G.M. Joffe, J.K. Vasey, P. Harland, S.J. Logue, J. Daugaard, G. Hain, S.F. Kirk, S.J. MacKewn, J.E. Stenning, S.P. NCRI Testis Tumour Clinical Study Group, (2007). 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J clin oncol, Vol.25 (21), pp. 3090-3095.  show abstract

Linger, R. Dudakia, D. Huddart, R. Easton, D. Bishop, D.T. Stratton, M.R. Rapley, E.A. (2007). A physical analysis of the Y chromosome shows no additional deletions, other than Gr/Gr, associated with testicular germ cell tumour. Br j cancer, Vol.96 (2), pp. 357-361.  show abstract

Crockford, G.P. Linger, R. Hockley, S. Dudakia, D. Johnson, L. Huddart, R. Tucker, K. Friedlander, M. Phillips, K.-. Hogg, D. Jewett, M.A. Lohynska, R. Daugaard, G. Richard, S. Chompret, A. Bonaïti-Pellié, C. Heidenreich, A. Albers, P. Olah, E. Geczi, L. Bodrogi, I. Ormiston, W.J. Daly, P.A. Guilford, P. Fosså, S.D. Heimdal, K. Tjulandin, S.A. Liubchenko, L. Stoll, H. Weber, W. Forman, D. Oliver, T. Einhorn, L. McMaster, M. Kramer, J. Greene, M.H. Weber, B.L. Nathanson, K.L. Cortessis, V. Easton, D.F. Bishop, D.T. Stratton, M.R. Rapley, E.A. (2006). Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum mol genet, Vol.15 (3), pp. 443-451.  show abstract

Murthy, V. Norman, A.R. Shahidi, M. Parker, C.C. Horwich, A. Huddart, R.A. Bange, A. Dearnaley, D.P. (2006). Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer. Bju int, Vol.97 (3), pp. 476-479.  show abstract

Jackson, A.S. Sohaib, S.A. Staffurth, J.N. Huddart, R.A. Parker, C.C. Horwich, A. Dearnaley, D.P. (2006). Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy. Clin oncol (r coll radiol), Vol.18 (2), pp. 109-116.  show abstract

Horwich, A. Shipley, J. Huddart, R. (2006). Testicular germ-cell cancer. Lancet, Vol.367 (9512), pp. 754-765.  show abstract

Horwich, A. Huddart, R. (2006). Retroperitoneal lymph-node dissection after chemotherapy for germ cell cancer in patients with elevated tumor markers. Nat clin pract urol, Vol.3 (5), pp. 250-251.

Birtle, A.J. Huddart, R.A. (2006). Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. Bju int, Vol.97 (6), p. 1348.

O'Doherty, U.M. McNair, H.A. Norman, A.R. Miles, E. Hooper, S. Davies, M. Lincoln, N. Balyckyi, J. Childs, P. Dearnaley, D.P. Huddart, R.A. (2006). Variability of bladder filling in patients receiving radical radiotherapy to the prostate. Radiother oncol, Vol.79 (3), pp. 335-340.  show abstract

Birtle, A.J. Huddart, R.A. (2006). Untitled. Bju int, Vol.97 (6), pp. 1348-1348.

Gilbert, D.C. Norman, A.R. Nicholl, J. Dearnaley, D.P. Horwich, A. Huddart, R.A. (2006). Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. Bju int, Vol.98 (1), pp. 67-69.  show abstract

Dalal, P.U. Sohaib, S.A. Huddart, R. (2006). Imaging of testicular germ cell tumours. Cancer imaging, Vol.6, pp. 124-134.  show abstract

Mangar, S.A. Foo, K. Norman, A. Khoo, V. Shahidi, M. Dearnaley, D.P. Horwich, A. Huddart, R.A. (2006). Evaluating the effect of reducing the high-dose volume on the toxicity of radiotherapy in the treatment of bladder cancer. Clin oncol (r coll radiol), Vol.18 (6), pp. 466-473.  show abstract

O'Sullivan, J.M. Norman, A.R. McCready, V.R. Flux, G. Buffa, F.M. Johnson, B. Coffey, J. Cook, G. Treleaven, J. Horwich, A. Huddart, R.A. Parker, C.C. Dearnaley, D.P. (2006). A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur j nucl med mol imaging, Vol.33 (9), pp. 1055-1061.  show abstract

Sharma, R.A. Wotherspoon, A.C. Cook, G. Morgan, G.J. Huddart, R.A. (2006). Neuron-specific enolase expression in multiple myeloma. Lancet oncol, Vol.7 (11), p. 960.

Huddart, R.A. Joffe, J.K. (2006). Preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin oncol (r coll radiol), Vol.18 (9), pp. 693-695.

Huddart, R. O'Doherty, M. Padhani, A. Rustin, G. Mead, G. Joffe, J.K. Vasey, P. Hain, S. Kirk, S.J. Stenning, S.P. National Cancer Research Institute Testis Cancer Clinical Studies Group, (2006). A prospective study of (18)FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. J clin oncol, Vol.24 (18_suppl), p. 4520.  show abstract

Mead, G.M. Rustin, G.J. Stenning, S.P. Vasey, P. Aass, N. Huddart, R. Sokal, M. Kirk, S. (2006). Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis. J clin oncol, Vol.24 (18_suppl), p. 4519.  show abstract

Coffey, J. Huddart, R.A. Norman, A.R. Dudakia, D. Stratton, M.R. Rapley, E.A. (2006). Characteristics of a single-centre series of familial testicular germ cell tumours. J clin oncol, Vol.24 (18_suppl), p. 10039.  show abstract

Harwich, A. Shipley, J. Huddart, R. (2006). Testicular germ-cell cancer (vol 367, pg 754, 2006). Lancet, Vol.367 (9520), pp. 1398-1398.

Mangar, S. Coffey, J. McNair, H. Hansen, V.N. Sohaib, S. Huddart, R. Parker, C. Horwich, A. Dearnaley, D. (2006). Prostate Radiotherapy: Evaluating the Effect of Bladder and Rectal Changes on Prostate Movement-A CT Study. Trends in medical research, Vol.1 (1), pp. 55-65.

Huddart, R.A. Birtle, A.J. (2005). Recent advances in the treatment of testicular cancer. Expert rev anticancer ther, Vol.5 (1), pp. 123-138.  show abstract

Mangar, S.A. Huddart, R.A. Parker, C.C. Dearnaley, D.P. Khoo, V.S. Horwich, A. (2005). Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur j cancer, Vol.41 (6), pp. 908-921.  show abstract

Horwich, A. Dearnaley, D. Huddart, R. Graham, J. Bessell, E. Mason, M. Bliss, J. (2005). A randomised trial of accelerated radiotherapy for localised invasive bladder cancer. Radiother oncol, Vol.75 (1), pp. 34-43.  show abstract

Birtle, A.J. Huddart, R.A. Horwich, A.H. Dearnaley, D.P. Alexander, Z. (2005). Can bleomycin toxicity in the treatment of testis cancer be batch related?. Ann oncol, Vol.16 (5), p. 837.

Jackson, A.S. Parker, C.C. Norman, A.R. Padhani, A.R. Huddart, R.A. Horwich, A. Husband, J.E. Dearnaley, D.P. (2005). Tumour staging using magnetic resonance imaging in clinically localised prostate cancer: relationship to biochemical outcome after neo-adjuvant androgen deprivation and radical radiotherapy. Clin oncol (r coll radiol), Vol.17 (3), pp. 167-171.  show abstract

Hardie, C. Parker, C. Norman, A. Eeles, R. Horwich, A. Huddart, R. Dearnaley, D. (2005). Early outcomes of active surveillance for localized prostate cancer. Bju int, Vol.95 (7), pp. 956-960.  show abstract

Doneux, A. Parker, C.C. Norman, A. Eeles, R. Howich, A. Huddart, R. Dearnaley, D. (2005). The utility of digital rectal examination after radical radiotherapy for prostate cancer. Clin oncol (r coll radiol), Vol.17 (3), pp. 172-173.  show abstract

Postma, T.J. Aaronson, N.K. Heimans, J.J. Muller, M.J. Hildebrand, J.G. Delattre, J.Y. Hoang-Xuan, K. Lantéri-Minet, M. Grant, R. Huddart, R. Moynihan, C. Maher, J. Lucey, R. EORTC Quality of Life Group, (2005). The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur j cancer, Vol.41 (8), pp. 1135-1139.  show abstract

Birtle, A.J. Horwich, A.H. Dearnaley, D.P. Shepherd, R. Huddart, R.A. (2005). Selective organ preservation in muscle-invasive TCC of the bladder: a biological approach. Bju int, Vol.95, pp. 22-22.

Khan, M.A. Norman, A. Huddart, R. Horwich, A. Christmas, T.J. (2005). Bone metastases from testicular tumours: management and outcomes. Bju int, Vol.95, pp. 6-7.

Cullen, M. Steven, N. Billingham, L. Gaunt, C. Hastings, M. Simmonds, P. Stuart, N. Rea, D. Bower, M. Fernando, I. Huddart, R. Gollins, S. Stanley, A. Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group, (2005). Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N engl j med, Vol.353 (10), pp. 988-998.  show abstract

Coffey, J. Birtle, A.J. Cogill, G. Christmas, T.J. Rapley, E.A. Huddart, R.A. (2005). A discussion of the biology of testicular cancer and current concepts in the management of stage I and bilateral disease. Clin oncol (r coll radiol), Vol.17 (6), pp. 441-447.  show abstract

Sirohi, B. Huddart, R. (2005). The management of poor-prognosis, non-seminomatous germ-cell tumours. Clin oncol (r coll radiol), Vol.17 (7), pp. 543-552.  show abstract

Huddart, R. O'Doherty, M. Padhani, A. Rustin, G. Mead, G. Seiby, P. Vasey, P. Wow, M. Kirk, S. Stenning, S. (2005). A prospective study of 18FDG PET in the prediction of relapse in patients with high risk clinical stage I non-seminomatous germ cell cancer (MRC study TE22). Ejc suppl, Vol.3 (2), pp. 227-228.

Huddart, R. Birtle, A. Shephard, R. (2005). Selective organ preservation in muscle-invasive TCC of the bladder: a biological approach. Ejc suppl, Vol.3 (2), pp. 254-254.

McIntyre, A. Summersgill, B. Spendlove, H.E. Huddart, R. Houlston, R. Shipley, J. (2005). Activating mutations and/or expression levels of tyrosine kinase receptors GRB7, RAS, and BRAF in testicular germ cell tumors. Neoplasia, Vol.7 (12), pp. 1047-1052.  show abstract

Nathanson, K.L. Kanetsky, P.A. Hawes, R. Vaughn, D.J. Letrero, R. Tucker, K. Friedlander, M. Phillips, K.-. Hogg, D. Jewett, M.A. Lohynska, R. Daugaard, G. Richard, S. Chompret, A. Bonaïti-Pellié, C. Heidenreich, A. Olah, E. Geczi, L. Bodrogi, I. Ormiston, W.J. Daly, P.A. Oosterhuis, J.W. Gillis, A.J. Looijenga, L.H. Guilford, P. Fosså, S.D. Heimdal, K. Tjulandin, S.A. Liubchenko, L. Stoll, H. Weber, W. Rudd, M. Huddart, R. Crockford, G.P. Forman, D. Oliver, D.T. Einhorn, L. Weber, B.L. Kramer, J. McMaster, M. Greene, M.H. Pike, M. Cortessis, V. Chen, C. Schwartz, S.M. Bishop, D.T. Easton, D.F. Stratton, M.R. Rapley, E.A. (2005). The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am j hum genet, Vol.77 (6), pp. 1034-1043.  show abstract

Dearnaley, D.P. Hall, E. Lawrence, D. Huddart, R.A. Eeles, R. Nutting, C.M. Gadd, J. Warrington, A. Bidmead, M. Horwich, A. (2005). Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br j cancer, Vol.92 (3), pp. 488-498.  show abstract

McIntyre, A. Summersgill, B. Grygalewicz, B. Gillis, A.J. Stoop, J. van Gurp, R.J. Dennis, N. Fisher, C. Huddart, R. Cooper, C. Clark, J. Oosterhuis, J.W. Looijenga, L.H. Shipley, J. (2005). Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer res, Vol.65 (18), pp. 8085-8089.  show abstract

Huddart, R.A. Norman, A. Moynihan, C. Horwich, A. Parker, C. Nicholls, E. Dearnaley, D.P. (2005). Fertility, gonadal and sexual function in survivors of testicular cancer. Br j cancer, Vol.93 (2), pp. 200-207.  show abstract

Mead, G.M. Cullen, M.H. Huddart, R. Harper, P. Rustin, G.J. Cook, P.A. Stenning, S.P. Mason, M. MRC Testicular Tumour Working Party, (2005). A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br j cancer, Vol.93 (2), pp. 178-184.  show abstract

Huddart, R.A. Purkalne, G. ESMO Guidelines Task Force, (2005). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT). Ann oncol, Vol.16 Suppl 1, pp. i37-i39.

Parker, C. Warde, P. Norman, A. Panzarella, T. Catton, C. Horwich, A. Huddart, R. Dearnaley, D. (2004). The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivation. Int j radiat oncol biol phys, Vol.58 (1), pp. 53-58.  show abstract

McIntyre, A. Summersgill, B. Jafer, O. Rodriguez, S. Zafarana, G. Oosterhuis, J.W. Gillis, A.J. Looijenga, L. Cooper, C. Huddart, R. Clark, J. Shipley, J. (2004). Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene, Vol.23 (56), pp. 9142-9147.  show abstract

Horwich, A. Huddart, R. (2004). Conservative treatment of bladder cancer. Clin oncol (r coll radiol), Vol.16 (3), pp. 163-165.

Morris, S.L. Parker, C. Huddart, R. Horwich, A. Dearnaley, D. (2004). Current opinion on adjuvant and salvage treatment after radical prostatectomy. Clin oncol (r coll radiol), Vol.16 (4), pp. 277-282.  show abstract

Schmoll, H.J. Souchon, R. Krege, S. Albers, P. Beyer, J. Kollmannsberger, C. Fossa, S.D. Skakkebaek, N.E. de Wit, R. Fizazi, K. Droz, J.P. Pizzocaro, G. Daugaard, G. de Mulder, P.H. Horwich, A. Oliver, T. Huddart, R. Rosti, G. Paz Ares, L. Pont, O. Hartmann, J.T. Aass, N. Algaba, F. Bamberg, M. Bodrogi, I. Bokemeyer, C. Classen, J. Clemm, S. Culine, S. de Wit, M. Derigs, H.G. Dieckmann, K.P. Flasshove, M. Garcia del Muro, X. Gerl, A. Germa-Lluch, J.R. Hartmann, M. Heidenreich, A. Hoeltl, W. Joffe, J. Jones, W. Kaiser, G. Klepp, O. Kliesch, S. Kisbenedek, L. Koehrmann, K.U. Kuczyk, M. Laguna, M.P. Leiva, O. Loy, V. Mason, M.D. Mead, G.M. Mueller, R.P. Nicolai, N. Oosterhof, G.O. Pottek, T. Rick, O. Schmidberger, H. Sedlmayer, F. Siegert, W. Studer, U. Tjulandin, S. von der Maase, H. Walz, P. Weinknecht, S. Weissbach, L. Winter, E. Wittekind, C. European Germ Cell Cancer Consensus Group, (2004). European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann oncol, Vol.15 (9), pp. 1377-1399.  show abstract

Rapley, E.A. Hockley, S. Warren, W. Johnson, L. Huddart, R. Crockford, G. Forman, D. Leahy, M.G. Oliver, D.T. Tucker, K. Friedlander, M. Phillips, K.-. Hogg, D. Jewett, M.A. Lohynska, R. Daugaard, G. Richard, S. Heidenreich, A. Geczi, L. Bodrogi, I. Olah, E. Ormiston, W.J. Daly, P.A. Looijenga, L.H. Guilford, P. Aass, N. Fosså, S.D. Heimdal, K. Tjulandin, S.A. Liubchenko, L. Stoll, H. Weber, W. Einhorn, L. Weber, B.L. McMaster, M. Greene, M.H. Bishop, D.T. Easton, D. Stratton, M.R. (2004). Somatic mutations of KIT in familial testicular germ cell tumours. Br j cancer, Vol.90 (12), pp. 2397-2401.  show abstract

Feber, A. Clark, J. Goodwin, G. Dodson, A.R. Smith, P.H. Fletcher, A. Edwards, S. Flohr, P. Falconer, A. Roe, T. Kovacs, G. Dennis, N. Fisher, C. Wooster, R. Huddart, R. Foster, C.S. Cooper, C.S. (2004). Amplification and overexpression of E2F3 in human bladder cancer. Oncogene, Vol.23 (8), pp. 1627-1630.  show abstract

O'Sullivan, J.M. Huddart, R.A. Norman, A.R. Nicholls, J. Dearnaley, D.P. Horwich, A. (2003). Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann oncol, Vol.14 (1), pp. 91-96.  show abstract

Christian, J.A. Huddart, R.A. Norman, A. Mason, M. Fossa, S. Aass, N. Nicholl, E.J. Dearnaley, D.P. Horwich, A. (2003). Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J clin oncol, Vol.21 (5), pp. 871-877.  show abstract

Huddart, R.A. (2003). Use of FDG-PET in testicular tumours. Clin oncol (r coll radiol), Vol.15 (3), pp. 123-127.

Moynihan, C. Burton, S. Huddart, R. Dearnaley, D. Horwich, A. (2003). Men's understanding of genetic cancer with special reference to prostate and testicular disease: an exploratory study. Psycho-oncol, Vol.12 (4), pp. S164-S164.

Watson, M. Lintz, K. Moynihan, C. Steginga, S. Norman, A. Huddart, R. Dearnaley, D. (2003). Need for support and psychological care in prostate cancer patients. Psycho-oncol, Vol.12 (4), pp. S143-S143.

Huddart, R.A. (2003). Improving treatment outcomes in testicular cancer: strategies to reduce treatment related morbidity. Bju int, Vol.92 (6), pp. 524-526.

Lintz, K. Moynihan, C. Steginga, S. Norman, A. Eeles, R. Huddart, R. Dearnaley, D. Watson, M. (2003). Prostate cancer patients' support and psychological care needs: Survey from a non-surgical oncology clinic. Psychooncology, Vol.12 (8), pp. 769-783.  show abstract

Huddart, R.A. Norman, A. Shahidi, M. Horwich, A. Coward, D. Nicholls, J. Dearnaley, D.P. (2003). Cardiovascular disease as a long-term complication of treatment for testicular cancer. J clin oncol, Vol.21 (8), pp. 1513-1523.  show abstract

Huddart, R.A. Norman, A. (2003). Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy. Br j cancer, Vol.89 (6), pp. 1143-1144.

Huddart, R.A. Norman, A. (2003). Long-term survivors of testicular cancer - In reply. J clin oncol, Vol.21 (20), pp. 3888-3889.

Bollet, M.A. McNair, H.A. Hansen, V.N. Norman, A. O'Doherty, U. Taylor, H. Rose, M. Mukherjee, R. Huddart, R. (2003). Can digitally reconstructed radiographs (DRRS) replace simulation films in prostate cancer conformal radiotherapy?. Int j radiat oncol biol phys, Vol.57 (4), pp. 1122-1130.  show abstract

Rodriguez, S. Jafer, O. Goker, H. Summersgill, B.M. Zafarana, G. Gillis, A.J. van Gurp, R.J. Oosterhuis, J.W. Lu, Y.-. Huddart, R. Cooper, C.S. Clark, J. Looijenga, L.H. Shipley, J.M. (2003). Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11 2-p12 1. Oncogene, Vol.22 (12), pp. 1880-1891.  show abstract

Shahidi, M. Norman, A.R. Dearnaley, D.P. Nicholls, J. Horwich, A. Huddart, R.A. (2002). Late recurrence in 1263 men with testicular germ cell tumors Multivariate analysis of risk factors and implications for management. Cancer, Vol.95 (3), pp. 520-530.  show abstract

O'Sullivan, J. Treleaven, J. McCready, V. Norman, A. Horwich, A. Huddart, R. Dearnaley, D. (2002). Autologous peripheral blood stem cell rescue permits administration of high activities of rhenium-186 HEDP in progressive hormone refractory prostate cancer metastatic to bone. Bone marrow transpl, Vol.29, pp. S44-S44.

Parker, C.C. Norman, A.R. Huddart, R.A. Horwich, A. Dearnaley, D.P. (2002). Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Br j cancer, Vol.86 (5), pp. 686-691.  show abstract

Parker, C.C. Norman, A.R. Huddart, R.A. Horwich, A. Dearnaley, D.P. (2002). Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Brit j cancer, Vol.86 (5), pp. 686-691.  show abstract

Hardy, J.R. Huddart, R. (2002). Spinal cord compression--what are the treatment standards?. Clin oncol (r coll radiol), Vol.14 (2), pp. 132-134.

O'Sullivan, J.M. McCready, V.R. Flux, G. Norman, A.R. Buffa, F.M. Chittenden, S. Guy, M. Pomeroy, K. Cook, G. Gadd, J. Treleaven, J. Al-Deen, A. Horwich, A. Huddart, R.A. Dearnaley, D.P. (2002). High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br j cancer, Vol.86 (11), pp. 1715-1720.  show abstract

Horwich, A. Huddart, R.A. (2002). Adjuvant chemotherapy for high-risk low-stage germ-cell tumours. Curr opin urol, Vol.12 (5), pp. 431-434.  show abstract

Moynihan, C. Burton, M. Huddart, R. Dearnaley, D. Horwich, A. (2002). An exploration into male communication in the context of genetic disease: With special reference to prostate and testicular cancer. Psycho-oncol, Vol.11 (6), pp. 554-555.

Watson, M. Lintz, K. Moynihan, C. Steginga, S. Norman, A. Huddart, R. Dearnaley, D. (2002). Need for support and psychological care in prostate cancer patients. Psycho-oncol, Vol.11 (6), pp. 557-557.

Schwarz, A.J. Maisey, N.R. Collins, D.J. Cunningham, D. Huddart, R. Leach, M.O. (2002). Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br j radiol, Vol.75 (900), pp. 959-966.  show abstract

Hendry, W.F. Norman, A.R. Dearnaley, D.P. Fisher, C. Nicholls, J. Huddart, R.A. Horwich, A. (2002). Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer, Vol.94 (6), pp. 1668-1676.  show abstract

Patterson, H. Norman, A.R. Mitra, S.S. Nicholls, J. Fisher, C. Dearnaley, D.P. Horwich, A. Mason, M.D. Huddart, R.A. (2001). Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother oncol, Vol.59 (1), pp. 5-11.  show abstract

Huddart, R.A. Norman, A. Moynihan, C. Coward, D. Nicholls, J. Jay, G. Shahidi, M. Horwich, A. Dearnaley, D. (2001). Fertility and quality of life after treatment for testicular cancer. Brit j cancer, Vol.85, pp. 27-27.

Huddart, R.A. Staffurth, J.N. Adams, E.J. Hansen, V.N. (2001). Could conformal (CFRT) or intensity modulated radiotherapy (IMRT) reduce toxicity in the radiotherapy (RT) of bladder cancer?. Brit j cancer, Vol.85, pp. 54-54.

Highley, M. Griffiths, G. Uscinska, B. Harper, P. Huddart, R. Barber, J. MRC Bladder Canc Working Party, (2001). A phase II trial of continuous 5-fluorouracil (5-FU) in recurrent locally advanced or metastatic transitional cell carcinoma of the urinary tract. Brit j cancer, Vol.85, pp. 52-52.

Huddart, R.A. ESMO Guidelines Task Force, (2001). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumours (NSGCT). Ann oncol, Vol.12 (9), pp. 1215-1216.

Nutting, C.M. Huddart, R.A. (2001). Retinoids in the prevention of bladder cancer. Expert rev anticancer ther, Vol.1 (4), pp. 541-545.  show abstract

Faithfull, S. Corner, J. Meyer, L. Huddart, R. Dearnaley, D. (2001). Evaluation of nurse-led follow up for patients undergoing pelvic radiotherapy. Br j cancer, Vol.85 (12), pp. 1853-1864.  show abstract

Summersgill, B.M. Jafer, O. Wang, R. Goker, H. Niculescu-Duvaz, I. Huddart, R. Shipley, J. (2001). Definition of chromosome aberrations in testicular germ cell tumor cell lines by 24-color karyotyping and complementary molecular cytogenetic analyses. Cancer genet cytogenet, Vol.128 (2), pp. 120-129.  show abstract

Summersgill, B. Osin, P. Lu, Y.J. Huddart, R. Shipley, J. (2001). Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adults. Br j cancer, Vol.85 (2), pp. 213-220.  show abstract

Cook, A.M. Dzik-Jurasz, A.S. Padhani, A.R. Norman, A. Huddart, R.A. (2001). The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Br j cancer, Vol.85 (11), pp. 1624-1626.  show abstract

Dearnaley, D. Huddart, R. Horwich, A. (2001). Regular review: Managing testicular cancer. Bmj, Vol.322 (7302), pp. 1583-1588.

Huddart, R.A. Lau, F.N. Guerrero-Urbano, T. Jay, G. Norman, A. Horwich, A. Dearnaley, D.P. (2001). Accelerated chemotherapy in the treatment of urothelial cancer. Clin oncol (r coll radiol), Vol.13 (4), pp. 279-283.  show abstract

Shahidi, M. Norman, A.R. Gadd, J. Huddart, R.A. Horwich, A. Dearnaley, D.P. (2001). Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin oncol (r coll radiol), Vol.13 (4), pp. 291-295.  show abstract

Rapley, E.A. Crockford, G.P. Teare, D. Biggs, P. Seal, S. Barfoot, R. Edwards, S. Hamoudi, R. Heimdal, K. Fossâ, S.D. Tucker, K. Donald, J. Collins, F. Friedlander, M. Hogg, D. Goss, P. Heidenreich, A. Ormiston, W. Daly, P.A. Forman, D. Oliver, T.D. Leahy, M. Huddart, R. Cooper, C.S. Bodmer, J.G. Easton, D.F. Stratton, M.R. Bishop, D.T. (2000). Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat genet, Vol.24 (2), pp. 197-200.  show abstract

Staffurth, J. Nichols, J. Huddart, R.A. Dearnaley, D.P. Horwich, A. (2000). Study of paclitaxel regimens in the treatment of platinum refractory and multiply relapsed germ cell tumours. Ann oncol, Vol.11, pp. 78-78.

Bonar, J. Huddart, R. Norman, A. Nicholls, J. Dearnaley, D. Horwich, A. (2000). CBOP/BEP accelerated induction chemotherapy in poor prognosis germ cell tumours (GCT) The Royal Marsden Hospital Experience. Ann oncol, Vol.11, pp. 74-74.

Hain, S.F. O'Doherty, M.J. Timothy, A.R. Leslie, M.D. Partridge, S.E. Huddart, R.A. (2000). Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur j nucl med, Vol.27 (5), pp. 590-594.  show abstract

Nutting, C. Huddart, R.A. (2000). Rethinking the secondary prevention of superficial bladder cancer: is there a role for retinoids?. Bju int, Vol.85 (9), pp. 1023-1026.

Cook, A.M. Huddart, R.A. Jay, G. Norman, A. Dearnaley, D.P. Horwich, A. (2000). The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br j cancer, Vol.82 (12), pp. 1952-1957.  show abstract

Stone, P. Hardy, J. Huddart, R. A'Hern, R. Richards, M. (2000). Fatigue in patients with prostate cancer receiving hormone therapy. Eur j cancer, Vol.36 (9), pp. 1134-1141.  show abstract

Huddart, R.A. Norman, A. Coward, D. Nicholls, E. Jay, G. Shahidi, M. Horwich, A. Dearnaley, D.P. (2000). The effect of treatment on the health of long term survivors of testicular cancer. Brit j cancer, Vol.83, pp. 77-77.

Staffurth, J.N. Nichols, J. Huddart, R.A. Dearnaley, D.P. Horwich, A. (2000). Paclitaxel chemotherapy in the salvage of multiply relapsed and platinum refractory germ cell tumours. Brit j cancer, Vol.83, pp. 77-77.

Shahidi, M. Norman, A.R. Nicholls, J. Dearnaley, D.P. Huddart, R.A. Horwich, A. (2000). Late relapse of testicular germ cell tumours and implications on long term follow up. Brit j cancer, Vol.83, pp. 78-78.

Dearnaley, D.P. Parker, C. Norman, A. Huddart, R. Horwich, A. (2000). A model to predict biochemical (PSA) control after radical radiotherapy with initial androgen suppression for clinically localised prostate cancer. Brit j cancer, Vol.83, pp. 74-74.

Moynihan, C. Burton, S. Huddart, R. Eeles, R. Dearnaley, D. Horwich, A. (2000). Men's understanding of genetic cancer. Psycho-oncol, Vol.9 (5), pp. S36-S36.

Hain, S.F. O'Doherty, M.J. Timothy, A.R. Leslie, M.D. Harper, P.G. Huddart, R.A. (2000). Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br j cancer, Vol.83 (7), pp. 863-869.  show abstract

Mitchell, G. Huddart, R. Harmer, C. (1999). Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother oncol, Vol.50 (1), pp. 33-38.  show abstract

Visioli, A.G. Rivens, I.H. ter Haar, G.R. Horwich, A. Huddart, R.A. Moskovic, E. Padhani, A. Glees, J. (1999). Preliminary results of a phase I dose escalation clinical trial using focused ultrasound in the treatment of localised tumours. Eur j ultrasound, Vol.9 (1), pp. 11-18.  show abstract

Teh, B.T. Linblad, K. Nord, B. Kytölä, S. Schalling, M. Larsson, C. Rapley, E. Biggs, P. Huddart, R. Stratton, M. (1999). Familial testicular cancer: lack of evidence for trinucleotide repeat expansions and association with PKD1 in one family. J med genet, Vol.36 (4), pp. 348-349.

Hain, S.F. O'Doherty, M.J. Huddart, R.A. Leslie, M.D. Timothy, A.R. Harper, P.G. (1999). The value of FDG-PET in recurrent testicular carcinoma. J nucl med, Vol.40 (5), pp. 105P-105P.

Huddart, R.A. Norman, A. Shahldi, D.P. Deamaley, D.P. Horwich, A. (1999). The effect of reducing the high dose volume on toxicity of radiotherapy in the treatment of bladder cancer. Brit j cancer, Vol.80, pp. 17-17.

Cook, A.M. Huddart, R.A. Jay, G. Norman, A. Dearnaley, D.P. Horwich, A. (1999). The use of tumour markers in assessing response to chemotherapy in advanced bladder cancer. Brit j cancer, Vol.80, pp. 68-68.

Shahidi, M. Norman, A.R. Huddart, R.A. Jay, G. Fisher, C. Dearnaley, D.P. Horwich, A. (1999). A report of 13 cases of small cell carcinoma of the bladder. Brit j cancer, Vol.80, pp. 68-68.

Hain, S. O'Doherty, M. Leslie, M. Timothy, A. Harper, P.G. Huddart, R.A. (1999). The value of FDG-PET in recurrent testicular carcinoma. Brit j cancer, Vol.80, pp. 109-109.

Cook, A.M. Dzik-Jurasz, A. Padani, A. Norman, A. Huddart, R.A. (1999). The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours. Brit j cancer, Vol.80, pp. 111-111.

Stettner, A.R. Hartenbach, E.M. Schink, J.C. Huddart, R. Becker, J. Pauli, R. Long, R. Laxova, R. (1999). Familial ovarian germ cell cancer: report and review. Am j med genet, Vol.84 (1), pp. 43-46.  show abstract

Horwich, A. Dearnaley, D.P. Huddart, R. Graham, J. Bessel, E. Mason, M. Meyer, L. (1999). A trial of accelerated fractionation (AF) in T2/3 bladder cancer. Eur j cancer, Vol.35, pp. S342-S342.

Horwich, A. Huddart, R. Dearnaley, D. (1999). Management of germ cell tumours of the testis - Reply. Lancet, Vol.353 (9150), pp. 410-410.

Cook, A.M. Patterson, H. Nicholls, J. Huddart, R.A. (1999). Avascular necrosis in patients treated with BEP chemotherapy for testicular tumours. Clin oncol (r coll radiol), Vol.11 (2), pp. 126-127.  show abstract

Jose, C.C. Price, A. Norman, A. Jay, G. Huddart, R. Dearnaley, D.P. Horwich, A. (1999). Hypofractionated radiotherapy for patients with carcinoma of the bladder. Clin oncol (r coll radiol), Vol.11 (5), pp. 330-333.  show abstract

Horwich, A. Huddart, R.A. Gadd, J. Boyd, P.J. Hetherington, J.W. Whelan, P. Dearnaley, D.P. (1998). A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br j urol, Vol.81 (1), pp. 96-99.  show abstract

Wilson, J. Khoo, V. Meyer, L. Bidmead, M. Warrington, J. Helyer, S. Gadd, J. Huddart, R. Horwich, A. Dearnaley, D. (1998). Randomized trial of high dose conformal radiotherapy for prostate cancer: Initial report of acute toxicity. Brit j cancer, Vol.78, pp. 8-8.

Mitchell, G. Huddart, R. Harmer, C.L. (1998). Phase II evaluation of high dose accelerated radiotherapy for locally advanced and anaplastic thyroid carcinoma. Brit j cancer, Vol.78, pp. 37-37.

Horwich, A. Huddart, R. Dearnaley, D. (1998). Markers and management of germ-cell tumours of the testes. Lancet, Vol.352 (9139), pp. 1535-1538.

Summersgill, B. Goker, H. Osin, P. Huddart, R. Horwich, A. Fisher, C. Shipley, J. (1998). Establishing germ cell origin of undifferentiated tumors by identifying gain of 12p material using comparative genomic hybridization analysis of paraffin-embedded samples. Diagn mol pathol, Vol.7 (5), pp. 260-266.  show abstract

Summersgill, B. Goker, H. Weber-Hall, S. Huddart, R. Horwich, A. Shipley, J. (1998). Molecular cytogenetic analysis of adult testicular germ cell tumours and identification of regions of consensus copy number change. Br j cancer, Vol.77 (2), pp. 305-313.  show abstract

Horwich, A. Paluchowska, B. Norman, A. Huddart, R. Nicholls, J. Fisher, C. Husband, J. Dearnaley, D.P. (1997). Residual mass following chemotherapy of seminoma. Ann oncol, Vol.8 (1), pp. 37-40.  show abstract

Mitchell, G. Huddart, R. (1997). 5HT3 antagonists and radiotherapy. Ann oncol, Vol.8 (3), p. 302.

Huddart, R.A. Rajan, B. Law, M. Meyer, L. Dearnaley, D.P. (1997). Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother oncol, Vol.44 (3), pp. 229-236.  show abstract

Faithfull, S. Deamaley, D.P. Huddart, R.A. (1997). Randomised controlled trial of supportive care in radical pelvic radiotherapy: Does it influence radiation morbidity?. Eur j cancer, Vol.33, pp. 53-53.

Huddart, R.A. Thompson, C. Houlston, R. Huddart, R.A. Nicholls, E.J. Horwich, A. (1996). Familial predisposition to both male and female germ cell tumours?. J med genet, Vol.33 (1), p. 86.

Huddart, R.A. Nahum, A. Neal, A. McLean, M. Dearnaley, D.P. Law, M. Dyer, J. Tait, D. (1996). Accuracy of pelvic radiotherapy: prospective analysis of 90 patients in a randomised trial of blocked versus standard radiotherapy. Radiother oncol, Vol.39 (1), pp. 19-29.  show abstract

Parker, C.C. Huddart, R.A. (1996). Management of invasive bladder cancer. Br j hosp med, Vol.56 (5), pp. 213-218.

Huddart, R.A. Thompson, C. Nicholls, E.J. Horwich, A. Houlston, R. (1996). Familial predisposition to both male and female germ cell tumours?. Brit j cancer, Vol.73 (8), pp. 21-21.

Summersgill, B.M. Huddart, R.A. Fisher, C. Horwich, A. Shipley, J. (1996). Identification of isochromosome 12P and other chromosomal copy number changes in male germ cell tumours by comparative genomic hybridisation (CGH); A new diagnostic tool?. Brit j cancer, Vol.74, pp. 11-11.

Huddart, R.A. Nicholls, J. Fisher, C. Horwich, A. (1996). Clinical features of familial testicular cancer: A report of 61 families. Brit j cancer, Vol.74, pp. 27-27.

Huddart, R.A. Wooster, R. Horwich, A. Cooper, C.S. (1995). Microsatellite instability in human testicular germ cell tumours. Br j cancer, Vol.72 (3), pp. 642-645.  show abstract

Leahy, M.G. Tonks, S. Moses, J.H. Brett, A.R. Huddart, R. Forman, D. Oliver, R.T. Bishop, D.T. Bodmer, J.G. (1995). Candidate regions for a testicular cancer susceptibility gene. Hum mol genet, Vol.4 (9), pp. 1551-1555.  show abstract

Foster, K. Osborne, R.J. Huddart, R.A. Affara, N.A. Ferguson-Smith, M.A. Maher, E.R. (1995). Molecular genetic analysis of the von Hippel-Lindau disease (VHL) tumour suppressor gene in gonadal tumours. Eur j cancer, Vol.31A (13-14), pp. 2392-2395.  show abstract

Huddart, R.A. Titley, J. Robertson, D. Williams, G.T. Horwich, A. Cooper, C.S. (1995). Programmed cell death in response to chemotherapeutic agents in human germ cell tumour lines. Eur j cancer, Vol.31A (5), pp. 739-746.  show abstract

Huddart, R.A. Leahy, M.G. (1994). Screening for testicular cancer Familial predisposition ignored. Bmj, Vol.309 (6955), p. 665.

Huddart, R. Traish, D. Ashley, S. Moore, A. Brada, M. (1993). Management of spinal astrocytoma with conservative surgery and radiotherapy. Br j neurosurg, Vol.7 (5), pp. 473-481.  show abstract

Whitaker, S.J. Huddart, R.A. Wilson, C.B. Yarnold, J.R. (1992). Axillary nodes dissection in breast cancer. Lancet, Vol.340 (8813), p. 247.

Huddart, R.A. Hubbard, C.S. Dickinson, R.J. (1991). Biliary stenting for malignant jaundice A district hospital experience. Clin radiol, Vol.43 (2), pp. 103-106.  show abstract

Huddart, R. Moore, N.R. Williams, M.V. Dixon, A.K. (1990). Difficulties in the diagnosis of metastatic testicular teratoma. Br j radiol, Vol.63 (751), pp. 569-572.

Turnbull, C.A. Ruark, E. Seal, S. McDonald, H. Zhang, F. Elliot, A. Lau, K. Perdeaux, E. Rapley, E. Eeles, R. Peto, J. Kote-Jarai, Z. Muir, K. Nsengimana, J. Shipley, J. UKTCC, Bishop, D.T. Stratton, M. Easton, D.F. Huddart, R. Rahman, N. Identification of nine new loci for testicular cancer, including variants located near DAZL and PRDM14, genes involved in germ cell development. Nature genetics, .  show abstract

Verkooijen, H.M. Kerkmeijer, L. Fuller, C.D. Huddart, R. Faivre-Finn, C. Verheij, M. Mook, S. Sahgal, A. Hall, E. Schultz, C. R-IDEAL: A FRAMEWORK FOR SYSTEMATIC CLINICAL EVALUATION OF TECHNICAL INNOVATIONS IN RADIATION ONCOLOGY. Frontiers in oncology, .

Huddart, R. Birtle, A. Maynard, L. Beresford, M. Blazeby, J. Donovan, J. Kelly, J.D. Kirkbank, T. McLaren, D.B. Mead, G. Moynihan, C. Persad, R. Scrase, C. Lewis, R. Hall, E. Clinical and patient reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. British journal of urology (bju) international, .

Dearnaley, D. reis ferreira, M. khan, A. truelove, L. gao, A. parker, C. huddart, R. eeles, R. khoo, V. van as, N. A phase I/II dose escalation study of the use of intensity modulated radiotherapy (IMRT) to treat the prostate and pelvic nodes in patients with prostate cancer. International journal of radiation oncology • biology • physics, .

Hall, E. Huddart, R. Practice changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?. British journal of cancer, .

Tan, M. Attard, G. Huddart, R. Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. International journal of molecular sciences, Vol.19 (9), pp. 2568-2568.  show abstract

Hall, E. Porta, N. Huddart, R. Cruickshank, C. Burnett, S. Maynard, L. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European urology, .

Hall, E. Huddart, R. Lewis, R. Porta, N. Patient reported quality of life outcomes in patients treated for muscle invasive bladder cancer with radiotherapy +/- chemotherapy in the BC2001 phase III randomised controlled trial. European urology, .

Walsh, J.S. Marshall, H. Smith, I.L. Greenfield, D.M. Swain, J. Best, E. Ashton, J. Brown, J.M. Huddart, R. Coleman, R.E. Snowden, J.A. Ross, R.J. Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. Plos medicine, Vol.16 (11), pp. e1002960-e1002960.

Hall, E. Hafeez, S. McNair, H. Lewis, R. Huddart, R. Protocol for hypofractionated adaptive radiotherapy to the bladder within a multi-centre phase II randomised trial: radiotherapy planning and delivery guidance. Bmj open, .

Nason, G. Wood, L. Huddart, R.A. Albers, P. Rendon, R.A. Einhorn, L.H. Nichols, C.R. Kollmannsberger, C. Anson-Cartwright, L. Sweet, J. Warde, P. Jewett, M.A. Chung, P. Bedard, P.L. Hansen, A.R. Hamilton, R. A Canadian approach to the regionalization of testis cancer: A review. Canadian urological association journal, Vol.14 (10).  show abstract

Jones, R. Crabb, S. Chester, J. Elliott, T. Huddart, R. Birtle, A. Evans, L. Lester, J. Jagdev, S. Casbard, A. Huang, C. Madden, T.-. Griffiths, G. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. Bju international, .

Nason, G.J. Chung, P. Warde, P. Huddart, R. Albers, P. Kollmannsberger, C. Booth, C.M. Hansen, A.R. Bedard, P.L. Einhorn, L. Nichols, C. Rendon, R.A. Wood, L. Jewett, M.A. Hamilton, R.J. Controversies in the management of clinical stage 1 testis cancer. Canadian urological association journal, Vol.14 (11).  show abstract

Hall, E. Huddart, R. Oelfke, U. Harrington, K. The MOMENTUM study: an International Registry for the Evidence-Based Introduction of MR-guided Adaptive Therapy. Frontiers in oncology, .

Hall, E. Hafeez, S. Huddart, R. Lewis, R. Griffin, C. Failing to close the gap between evidence and clinical practice in radical bladder cancer radiotherapy. Clinical oncology, .


Book Chapters

Huddart, R.A. Norman, A. Shahidi, M. Horwich, A. Coward, D. Nicholls, J. Dearnaley, D. (2002). Cardiovascular disease as a long term complication of treatment for testicular cancer. In Harden, P.Joffe, J.K.Jones, W.G. (Eds.), . (pp. 211-212). SPRINGER-VERLAG LONDON LTD. ISBN: 1-85233-563-7.

Huddart, R.A. Norman, A. Shahidi, M. Horwich, A. Coward, D. Nicholls, J. Dearnaley, D. (2002). Cardiovascular disease as a long term complication of treatment for testicular cancer. In Harden, P.Joffe, J.K.Jones, W.G. (Eds.), . (pp. 213-214). SPRINGER-VERLAG LONDON LTD. ISBN: 1-85233-563-7.

O'Sullivan, J.M. Norman, A.R. Nicholls, J. Huddart, R.A. Dearnaley, D.P. Horwich, A. (2002). Factors associated with bleomycin lung toxicity in germ cell tumour patients treated at the Royal Marsden Hospital between 1982 and 1999. In Harden, P.Joffe, J.K.Jones, W.G. (Eds.), . (pp. 217-218). SPRINGER-VERLAG LONDON LTD. ISBN: 1-85233-563-7.

Shahidi, M. Norman, A.R. Nicholls, J. Dearnaley, D.P. Horwich, A. Huddart, R.A. (2002). Multivariate analysis of predictive factors of late relapse in 1264 patients with testicular germ cell tumours. In Harden, P.Joffe, J.K.Jones, W.G. (Eds.), . (pp. 273-274). SPRINGER-VERLAG LONDON LTD. ISBN: 1-85233-563-7.


Conferences

Imkamp, F.Loriot, Y.Necchi, A.Park, S.H.Huddart, R.Burgess, E.Fu, M.Santiago-Walker, A.Mukhopadhyay, S.Naini, V.Deprince, K.Monga, M.Siefker-Radtke, A. (2020). Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Patients (PTS) with Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma (UC) and Selected FGFR Gene Alterations (FGFRALT): Phase 3 THOR Study, ONCOLOGY RESEARCH AND TREATMENT, Vol.43, p.78.

Nicol, D.Huddart, R.Reid, A.Sohaib, A.Hazell, S.Mayer, E. (2020). OUTCOMES WITH MINIMALLY INVASIVE RETROPERITONEAL LYMPH NODE DISSECTION (MI-RPLND) AND SINGLE DOSE CARBOPLATIN IN CLINICAL STAGE 2 SEMINOMA, JOURNAL OF UROLOGY, Vol.203, pp.E136-E137.

Hussain, S.A.Lester, J.F.Jackson, R.Gornall, M.Elliott, A.Crabb, S.J.Huddart, R.A.Vasudev, N.Birtle, A.J.Worlding, J.James, N.D.Parikh, O.Varela, M.V.Alonzi, R.Linch, M.D.Powles, T.Jones, R.J. (2020). Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE), JOURNAL OF CLINICAL ONCOLOGY, Vol.38 (6).

Huddart, R.A.Siefker-Radtke, A.O.Balar, A.V.Bilen, M.A.Powles, T.Bamias, A.Castellano, D.Khalil, M.F.Van der Heijden, M.S.Koshkin, V.S.Pook, D.W.Ozguroglu, M.Santiago, L.Saab, R.Li, P.-.Tagliaferri, M.C.Lin, W.Tagliaferri, M.A.Loriot, Y. (2020). PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC), JOURNAL OF CLINICAL ONCOLOGY, Vol.38 (6).

Beyer, J.Collette, L.Daugaard, G.De Wit, R.Tryakin, A.Albany, C.Stahl, O.Fizazi, K.Gietema, J.A.De Giorgi, U.Hansen, A.R.Feldman, D.R.Cafferty, F.Tandstad, T.del Muro, X.G.Huddart, R.A.Sweeney, C.Necchi, A.Assele, S.Gillessen, S.Consortium, I.G. (2020). Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium, JOURNAL OF CLINICAL ONCOLOGY, Vol.38 (6).

Subramaniam, S.Toner, G.C.Stockler, M.R.Martin, A.J.Pashankar, F.D.Frazier, A.L.Mazhar, D.Ford, K.Walpole, E.T.Stevanovic, A.G.Wyld, D.Troon, S.Hanning, F.J.Birtle, A.J.Wheater, M.J.Huddart, R.A.White, J.D.Spunt, S.L.Grimison, P.S.Urogenital, A.N. (2020). P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs), JOURNAL OF CLINICAL ONCOLOGY, Vol.38 (6).

Hussain, S.A.Ansari, J.Huddart, R.Power, D.G.Lyons, J.Wylie, J.Vilarino-Varlela, M.Elander, N.O.McMenemin, R.Pickering, L.M.Faust, G.Chauhan, S.Jackson, R.J. (2017). VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland, International Journal of Oncology, Vol.50 (3), pp.768-772.

Jones, R.J.Crabb, S.J.Chester, J.D.Elliott, T.Huddart, R.A.Birtle, A.J.Evans, L.Lester, J.F.Huang, C.Casbard, A.C.Madden, T.-.Griffiths, G. (2016). TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin., Journal of Clinical Oncology, Vol.34 (2_suppl), p.448.

Powles, T.Hussain, S.A.Protheroe, A.Birtle, A.Chakraborti, P.R.Huddart, R.Jagdev, S.Bahl, A.Stockdale, A.Sundar, S.Crabb, S.J.Dixon-Hughes, J.Alexander, L.Bray, C.A.Stobo, J.Wimalasingham, A.G.Ackerman, C.Paul, J.Jones, R. (2016). PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours., Journal of Clinical Oncology, Vol.34 (2_suppl), p.430.

Kelly, J.Maynard, L.Mostafid, H.Huddart, R.Bogle, R.Cresswell, J.Johnson, M.Protheroe, A.Burnett, S.Hall, E.BOXIT, T.M. (2015). Celecoxib for the treatment of non-muscle invasive bladder cancer (NMIBC): Results of the randomised BOXIT trial (CRUK/07/004), BJU INTERNATIONAL, Vol.115, pp.11-12.

Huddart, R.Porta, N.Lewis, R.Hendron, C.Hussein, S.James, N.Hall, E. (2015). Prognostic factors in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004), EUROPEAN JOURNAL OF CANCER, Vol.51, pp.S475-S476.

Wheater, M.Bowers, M.White, J.Rustin, G.Hennig, I.Cozens, K.Cross, N.Huddart, R.Mead, G. (2015). 2606 PET-CT as a predictor of recurrence after standard dose salvage chemotherapy for relapsed germ cell tumours. Results from the Gem-TIP study, European Journal of Cancer, Vol.51, pp.S513-S514.

Hussain, S.Jackson, R.Chauhan, S.Ansari, J.Huddart, R.Harrold, E.Power, D.Lyons, J.Wylie, J.Vilarino-Varela, M.Wilkinson, D.McMenemin, R.Pickering, L.Faust, G. (2015). 2632 VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium (TCCU): A retrospective analysis of the use of Vinflunine in a multi-centre real life setting as second line chemotherapy through the free of charge programme (FOCP) for patients in the UK, European Journal of Cancer, Vol.51, p.S523.

Fischer, S.Tandstad, T.Weather, M.Fléchon, A.Aparicio, J.Klingbiel, D.Skrbinc, B.Shamash, J.Lorch, A.Basso, U.Dieckmann, K.P.Huddart, R.Cohn-Cedermark, G.Ståhl, O.Chau, C.Arriola, E.Laguerre, B.Maroto, P.Beyer, J.Gillessen, S. (2015). 2601 Outcome of relapses after adjuvant carboplatin in clinical stage I seminoma, European Journal of Cancer, Vol.51, pp.S511-S512.

Carducci, M.Armstrong, A.Pili, R.Ng, S.Huddart, R.Agarwal, N.Khvorostenko, D.Lyulko, O.Brize, A.Vogelzang, N.J.Delva, R.Harza, M.Thanos, A.James, N.Werbrouck, P.Bögemann, M.Hutson, T.Milecki, P.Nederman, T.Sternberg, C. (2015). 4BA A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC), European Journal of Cancer, Vol.51, pp.S713-S714.

Lewis, R.Hafeez, S.McNair, H.Illambas, J.Friend, C.Hall, E.Huddart, R. (2015). Remote training solutions for complex intervention trials, Trials, Vol.16 (S2).

Porta, N.Calle, M.L.Lewis, R.Snape, M.Hendron, C.James, N.Huddart, R.Hall, E. (2015). Dynamic prediction methods in the BC2001 clinical trial, Trials, Vol.16 (S2).

Powles, T.Huddart, R.A.Elliott, T.Jones, R.Hussain, S.A.Crabb, S.J.Ackerman, C.Jagdev, S.Chester, J.D.Hilman, S.Beresford, M.Macdonald, A.G.Sundar, S.Frew, J.A.Stockdale, A.Sarker, S.-.Berney, D.Chowdhury, S. (2015). A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients., Journal of Clinical Oncology, Vol.33 (15_suppl), p.4505.

Hussain, S.A.Jackson, R.Shields, A.Dickinson, L.Cornford, P.Jones, R.J.Lester, J.F.Chester, J.D.Birtle, A.J.Powles, T.Crabb, S.J.Mazhar, D.Huddart, R.A.Protheroe, A.Azam, F.Vasudev, N.Butt, M.James, N.D. (2015). Phase II randomised placebo controlled neoadjuvant chemotherapy study of nintedanib with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer., Journal of Clinical Oncology, Vol.33 (15_suppl), p.TPS4574.

Wheater, M.J.Huddart, R.A.White, J.D.Rustin, G.J.Hennig, I.M.Cozens, K.Bowers, M.Cross, N.Mead, G. (2014). Salvage chemotherapy for relapsed germ cell tumors: A phase II trial of gemcitabine, paclitaxel, ifosfamide, and cisplatin (Gem-TIP)., Journal of Clinical Oncology, Vol.32 (15_suppl), p.4560.

Hafeez, S.Murray, J.Singhera, M.Huddart, R. (2013). Treatment and outcomes of non-transitional cell bladder cancer, EUROPEAN JOURNAL OF CANCER, Vol.49, p.S646.

Gilbert, D.C.Thway, K.Chandler, I.Al-Saadi, R.Gabe, R.Stenning, S.P.Shipley, J.Huddart, R.A. (2013). Prediction of relapse in stage I nonseminomatous germ cell tumors (NSGCT) by CXCL12: Results from the MRC TE08 and TE22 clinical trials, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (6).

Bahl, A.K.Huddart, R.A.Payne, H. (2013). Current management and proposal for guidance of radiation cystitis (RC): Results of a British Uro-oncology Group (BUG) survey, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (6).

Vinnicombe, S.Harland, S.J.Joffe, J.K.Huddart, R.Mazhar, D.Birtle, A.J.White, J.D.Wilson, P.Marshall, M.Sarker, S.-.Shamash, J. (2013). A randomized trial of 72-hour infusional bleomycin in BEP (cisplatin, etoposide, and bleomycin) versus conventional weekly bleomycin in patients with metastatic IGCCCG good prognosis disease, JOURNAL OF CLINICAL ONCOLOGY, Vol.31 (15).

Huddart, R.Birtle, A.Lewis, R.Bahl, A.Falconer, A.Maynard, L.Hall, E.SPARE, T.M. (2012). Results of the SPARE Feasibility Study - Selective Bladder Preservation Against Radical Excision in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder (CRUK/07/011), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.84 (3), pp.S119-S120.

Moynihan, C.Lewis, R.Hall, E.Jones, E.Birtle, A.Huddart, R.SPARE Trial Management Group, (2012). The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011)., England. Trials, Vol.13, p. 228.

Cook, G.Sohaib, A.Chua, S.Lewington, V.Huddart, R. (2011). The role of FDG PET/CT in testicular cancer, JOURNAL OF NUCLEAR MEDICINE, Vol.52.

McDonald, F.Lalondrelle, S.Harris, V.Taylor, H.Warren-Oseni, K.Hansen, V.Jones, K.Khoo, V.Huddart, R. (2011). 1187 poster DOSE-ESCALATED BLADDER RADIOTHERAPY: EARLY CLINICAL RESULTS, Radiotherapy and Oncology, Vol.99, pp.S442-S443.

Huddart, R. (2011). 548 speaker LEARNING LESSONS FROM THE PAST: THE PATH FORWARD AND NEW OPPORTUNITIES, Radiotherapy and Oncology, Vol.99, p.S224.

Huddart, R.A.Gabe, R.Stenning, S.P.Pollock, P.White, J.D.Cafferty, F.H.TE23 Trial Management Grp, (2011). Toxicity and Use of Granulocyte Colony-stimulating Factor Prophylaxis in a Randomized Phase II Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor Prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN53643604), Presented at European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm, SWEDEN. EUROPEAN JOURNAL OF CANCER, Vol.47, p.S517.

Paramasivan, S.Huddart, R.Hall, E.Lewis, R.Birtle, A.Donovan, J.L. (2011). Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011), TRIALS, Vol.12,

McDonald, F.Lalondrelle, S.Taylor, H.Harris, V.Hansen, V.N.Khoo, V.Huddart, R. (2010). DELIVERING ADAPTIVE RADIOTHERAPY IN THE CLINIC : PRELIMINARY EXPERIENCES FROM THE APPLY STUDY [ADAPTIVE-PREDICTIVE PLANNING FOR HYPO-FRACTIONATED BLADDER RADIOTHERAPY], RADIOTHERAPY AND ONCOLOGY, Vol.96, p.S177.

Taylor, H.Lalondrelle, S.McDonald, F.McNair, H.Huddart, R. (2010). DEVELOPING ADVANCED COMPETENCIES IN CBCT FOR THE IMPLEMENTATION OF ADAPTIVE BLADDER RADIOTHERAPY, RADIOTHERAPY AND ONCOLOGY, Vol.96, pp.S27-S28.

Harris, V.McDonald, F.Hansen, V.N.Taylor, H.Huddart, R. (2010). PLANNING OUTCOMES AND ACUTE TOXICITY OF INTENSITY MODULATED RADIOTHERAPY (IMRT) USED FOR SIMULTANEOUS TREATMENT OF BLADDER AND PELVIC NODES, RADIOTHERAPY AND ONCOLOGY, Vol.96, p.S361.

Fizazi, K.Blay, J.Bokemeyer, C.Germa, J.R.Henriksson, R.Huddart, R.A.Necchi, A.Piccart, M.Massard, C. (2010). HOW ARE DEPARTMENTS OF CANCER MEDICINE ORGANIZED IN EUROPE? RESULTS FROM A SURVEY CONDUCTED IN 7 COUNTRIES, Presented at 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, ITALY. ANNALS OF ONCOLOGY, Vol.21, p.339.

James, N.D.Hussain, S.A.Hall, E.Jenkins, P.Tremlett, J.Rawlings, C.Hendron, C.Lewis, R.Rogers, S.Huddart, R.A.Investigators, B. (2010). Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004), JOURNAL OF CLINICAL ONCOLOGY, Vol.28 (15).

James, N.Hussain, S.Hall, E.Jenkins, P.Tremlett, J.Rawlings, C.Crundwell, M.Waters, R.Huddart, R.A. (2010). Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004), Presented at 52nd Annual Meeting of the American-Society-For-Radiation-Oncology, San Diego, CA. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.78 (3), pp.S2-S3.

James, N.Hussain, S.Hall, E.Jenkins, P.Tremlett, J.Rawlings, C.Crundwell, M.Waters, R.Huddart, R.A. (2010). Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004), Presented at 52nd Annual Meeting of the American-Society-For-Radiation-Oncology, San Diego, CA. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.78 (3), pp.S2-S3.

McDonald, F.Hall, E.James, N.Huddart, R. (2009). Defining bowel dose constraints for bladder radiotherapy: using data from patients entered into phase III randomised trial, Presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY. EJC SUPPLEMENTS, Vol.7 (2), pp.163-164.

Huddart, R.James, N.D.Adab, F.Syndikus, I.Jenkins, P.Rawlings, C.Rogers, S.Lewis, R.Hendron, C.Hussain, S.Hall, E.BC2001 Investigators, (2009). Updated results of the BC2001 phase III randomized trial of standard vs reduced high dose volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339): tumour control, toxicity and quality of life, Presented at 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology, Berlin, GERMANY. EJC SUPPLEMENTS, Vol.7 (2), p.423.

Huddart, R.A.James, N.D.Adab, F.Syndikus, I.Jenkins, P.Rawlings, C.Hendron, C.Lewis, R.Rogers, S.Hall, E.BC2001 Investigators, (2009). BC2001: A multicenter phase III randomized trial of standard versus reduced volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339), Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Moynihan, C.Hall, E.Lewis, R.Birtle, A.Mead, G.M.Huddart, R.SPARE Trial Management Grp, (2009). SPARE: A qualitative study investigating randomization barriers in a Selective Bladder Preservation trial (SBP) (ISCRCTN: 61126465), Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Harland, S.J.Welch, R.Huddart, R.Stenning, S.Pollock, P.Gabe, R. (2009). On the necessity for postchemotherapy surgery for residual abdominal masses in metastatic nonseminomatous germ cell tumors (NSGCT) of testis, Presented at 45th Annual Meeting of the American-Society-of-Clinical-Oncology, Orlando, FL. JOURNAL OF CLINICAL ONCOLOGY, Vol.27 (15),

Huddart, R.Hall, E.James, N.Hussain, S.Crundwell, M.Tremlett, J.Jenkins, P.Rawlings, C.Rogers, S. (2008). EFFECT OF REDUCING RADIOTHERAPY VOLUME ON BLADDER TOXICITY: FIRST REPORT OF THE BC2001 TRIAL; A MULTICENTRE PHASE III RANDOMISED TRIAL OF STANDARD VERSUS REDUCED VOLUME RADIOTHERAPY TRIAL ISCRTN NO. 68324339, EUDRACT NO. 2004-000164-26, RADIOTHERAPY AND ONCOLOGY, Vol.88, pp.S19-S20.

James, N.Hussain, S.Rawlings, C.Jenkins, R.Tremlett, J.Crundwell, M.Huddart, R.Hall, E.Rogers, S. (2008). FIRST TOXICITY REPORT OF THE BC2001 TRIAL; A MULTICENTRE PHASE III RANDOMISED TRIAL OF RADIOTHERAPY WITH AND WITHOUT SYNCHRONOUS CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER ISCRTN NO. 68324339, EUDRACT NO. 2004-000164-26., RADIOTHERAPY AND ONCOLOGY, Vol.88, p.S298.

Huddart, R.A.Hall, E.James, N.Crundwell, M.Tremlett, J.Jenkins, P.Rawlings, C.Rogers, S. (2008). Effect of reducing radiotherapy volume on bladder toxicity: First report of the BC2001 trial; A multicenter phase III randomized trial of standard versus reduced volume radiotherapy trial iscrtn no. 68324339, eudract no. 2004-000164-26, Presented at 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology, Boston, MA. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.72 (1), pp.S292-S293.

James, N.D.Hussain, S.A.Tremlett, J.Crundwell, M.Jenkins, P.Rawlings, C.Hall, E.Rogers, S.Huddart, R. (2008). First toxicity report of the BC2001 trial: A multicentre phase III randomised trial or radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer ISCRTN no. 68324339, EUDRACT no. 2004-000164-26, Presented at 50th Annual Meeting of the American-Society-for-Therapeutic-Radiology-and Oncology, Boston, MA. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, Vol.72 (1), p.S7.

Huddart, R.Coffey, J.Elliot, F.Sohaib, A.Parker, E.Dudakia, D.Easton, D.F.Bishop, D.T.Stratton, M.R.Rapley, E.A. (2007). Testicular germ cell tumour and testicular microlithiasis; a familial association?, Presented at 14th European Cancer Conference (ECCO 14), Barcelona, SPAIN. EJC SUPPLEMENTS, Vol.5 (4), p.164.

Coffey, J.Huddart, R.A.Norman, A.R.Dudakia, D.Stratton, M.R.Rapley, E.A. (2006). Characteristics of a single-centre series of familial testicular germ cell tumours., Presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Atlanta, GA. JOURNAL OF CLINICAL ONCOLOGY, Vol.24 (18), p.550S.

Mead, G.M.Rustin, G.J.Stenning, S.P.Vasey, P.Aass, N.Huddart, R.Sokal, M.Kirk, S. (2006). Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis., Presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Atlanta, GA. JOURNAL OF CLINICAL ONCOLOGY, Vol.24 (18), p.221S.

Huddart, R.O'Doherty, M.Padhani, A.Rustin, G.Mead, G.Joffe, J.K.Vasey, P.Hain, S.Kirk, S.J.Stenning, S.P. (2006). A prospective study of (18)FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22., Presented at 42nd Annual Meeting of the American-Society-of-Clinical-Oncology, Atlanta, GA. JOURNAL OF CLINICAL ONCOLOGY, Vol.24 (18), p.222S.

Patel, H.Sandhu, S.S.Adshead, J.Norman, A.Huddart, R.Horwich, A.Christmas, T. (2004). Bone metastases from testicular tumours: Management and outcomes, Presented at 99th Annual Meeting of the American-Urological-Association, San Francisco, CA. JOURNAL OF UROLOGY, Vol.171 (4), p.246.

O'Doherty, U.M.McNair, H.A.Childs, P.J.Norman, A.Balyckyi, J.Huddart, R. (2003). The full bladder variable in radical prostate radiotherapy, Presented at 7th Biennial Meeting on Physics and Radiation Technology for Clinical Radiotherapy, Geneva, SWITZERLAND. RADIOTHERAPY AND ONCOLOGY, Vol.68, pp.S47-S48.

Cook, A.M.Dzik-Jurasz, A.S.Padhani, A.R.Norman, A.Huddart, R.A. (2002). The prevalence of avascular necrosis in patients treated with chemotherapy for testicular tumours, Presented at 5th Germ Cell Tumour Conference, UNIV LEEDS, DEVONSHIRE HALL, LEEDS, ENGLAND. GERM CELL TUMOURS V, , pp.215-216.

Huddart, R.A.Hain, S.F. (2002). FDG PET scanning in germ cell tumours, Presented at 5th Germ Cell Tumour Conference, UNIV LEEDS, DEVONSHIRE HALL, LEEDS, ENGLAND. GERM CELL TUMOURS V, , pp.257-267.

Summersgill, B.Jafer, O.Goker, H.Rodriguez, S.Huddart, R.Shipley, J. (2002). Investigating gain of 12p material in testicular germ cell tumours and its apparent absence in carcinoma in situ, Presented at 5th Germ Cell Tumour Conference, UNIV LEEDS, DEVONSHIRE HALL, LEEDS, ENGLAND. GERM CELL TUMOURS V, , pp.32-33.

Rapley, E.Tucker, K.Collins, F.Donald, J.Friedlander, M.Peng, H.Q.Goss, P.Hogg, D.Easton, D.F.Teare, D.Bishop, D.T.Crockford, G.Forman, D.Leahy, M.Bodmer, J.G.Moses, J.Tonks, S.Oliver, R.T.Biggs, P.Seal, S.Barfoot, R.Gill, S.Patel, S.Hamoudi, R.Hunter, R.Thomlinson, I.Cooper, C.Stratton, M.Huddart, R.Fossa, S.D.Heimdal, K.Int Testicular Cancer Linkage Consortium, (1998). Candidate regions for testicular cancer susceptibility genes, Presented at 4th Copenhagen Workshop on Carcinoma In Situ and Cancer of the Testis - Molecular and Endocrine Aspects, COPENHAGEN UNIV HOSP, COPENHAGEN, DENMARK. APMIS, Vol.106 (1), pp.64-70.

Summersgill, B.M.Huddart, R.A.Goker, H.Fisher, C.Horwich, A.Shipley, J. (1998). Comparative genomic hybridisation (CGH), a new diagnostic and research tool in adult male germ cell tumours (GCT), Presented at 4th Germ Cell Tumour Conference, LEEDS, ENGLAND. GERM CELL TUMOURS IV, , pp.87-88.

ter Haar, G.R.Rivens, I.H.Moskovic, E.Huddart, R.Visioli, A.G. (1998). Phase 1 clinical trial of the use of focused ultrasound surgery for the treatment of soft tissue tumours., Presented at Conference on Surgical Applications of Energy, SAN JOSE, CA. SURGICAL APPLICATIONS OF ENERGY, PROCEEDINGS OF, Vol.3249, pp.270-276.

HUDDART, R.A.TITLEY, J.L.PERA, M.HORWICH, A.COOPER, C.S. (1994). IS APOPTOSIS AN IMPORTANT MODE OF DEATH IN EMBRYONAL CARCINOMA, Presented at 3rd Germ Cell Tumour Conference, LEEDS, ENGLAND. GERM CELL TUMOURS III, Vol.91, p.149.